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A B S T R A C T
Central serous chorioretinopathy (CSC) is a common cause of central vision loss, primarily affecting men 20–60
years of age. To date, no consensus has been reached regarding the classification of CSC, and a wide variety of
interventions have been proposed, reflecting the controversy associated with treating this disease. The recent
publication of appropriately powered randomised controlled trials such as the PLACE trial, as well as large
retrospective, non-randomised treatment studies regarding the treatment of CSC suggest the feasibility of a more
evidence-based approach when considering treatment options. The aim of this review is to provide a compre-
hensive overview of the current rationale and evidence with respect to the variety of interventions available for
treating CSC, including pharmacology, laser treatment, and photodynamic therapy. In addition, we describe the
complexity of CSC, the challenges associated with treating CSC, and currently ongoing studies. Many treatment
strategies such as photodynamic therapy using verteporfin, oral mineralocorticoid antagonists, and micropulse
laser treatment have been reported as being effective. Currently, however, the available evidence suggests that
half-dose (or half-fluence) photodynamic therapy should be the treatment of choice in chronic CSC, whereas
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T
observation may be the preferred approach in acute CSC. Nevertheless, exceptions can be considered based upon
patient-specific characteristics.
1. Introduction
Central serous chorioretinopathy (CSC) is a chorioretinal disease
that causes idiopathic serous detachment of the retina, which is asso-
ciated with one or more areas of leakage from the choroid through a
defect in the retinal pigment epithelium (RPE) outer blood-retina bar-
rier. The majority of patients are men who have decreased and/or
distorted vision together with altered colour appreciation, and CSC is
generally associated with a decrease in the patient's quality of life
(Breukink et al., 2017; Sahin et al., 2014). The age at onset for CSC can
be as early as 7 years and as late as 83 years, with a peak at 40–50 years
(Castro-Correia et al., 1992; Fine and Owens, 1980; Gilbert et al., 1984;
Spaide et al., 1996a). CSC is relatively common, considered the fourth
most common non-surgical retinopathy associated with fluid leakage
(after neovascular age-related macular degeneration (AMD), diabetic
macular oedema, and retinal vein occlusion). Although the subretinal
fluid (SRF) can resolve spontaneously, many patients have significant
clinical sequelae, including atrophy of the RPE or retina, and patients
can also develop subretinal neovascularisation. The pathogenesis of
CSC remains poorly understood; however, choroidal abnormalities are
believed to be the primary underlying pathophysiology (Cardillo
Piccolino et al., 1995; Daruich et al., 2015; Guyer et al., 1994; Prunte
and Flammer, 1996; Spaide et al., 1996b). These abnormalities can
include choroidal thickening and hyperpermeability, together with in-
creased hydrostatic pressure, which has been hypothesised to induce
detachment of the RPE. These points of RPE detachment can remain
isolated, but breakdown of the outer blood-retina barrier can also cause
leakage of fluid into the subretinal space, resulting in active CSC. The
chronic presence of SRF can ultimately damage the RPE, although in
some cases the underlying multifocal choroidal vascular dysfunction
can directly affect the RPE without the presence of SRF (Gass, 1967;
Hayashi et al., 1986).
Central serous chorioretinopathy was first described as ‘relapsing
central luetic retinitis’ by Albrecht von Graefe more than 150 years ago
(von Graefe, 1866). In the 1930s, Kitahara changed the name to central
serous chorioretinitis, describing many of the clinical features asso-
ciated with the disease and hypothesising that the disease occurs sec-
ondary to tuberculosis (Kitahara, 1936). At around the same time,
Horniker called the condition ‘capillaro-spastic central retinitis’ and
postulated that the disease has a vascular origin (Horniker, 1927,
1937). In the 1940s, the condition was renamed ‘central serous re-
tinopathy’ by Duke-Elder (1940). At the time, the disease was believed
to occur secondary to spasms of the retinal vessels, which was believed
to cause a subretinal leakage of fluid. The majority of cases reported at
that time were military recruits in World War II; therefore, most of the
cases were young men.
Even back then, there was a focus on the autonomic nervous system.
For example, in 1955 Bennett noted from his review of the literature
and his personal analysis of patients with CSC that ‘ … while admitting
that certain individuals ‒ call them allergic, neurotic, endocrinopathic,
vasculospastic, or what you will ‒ are peculiarly susceptible to an at-
tack, we should not rule out an immediate essential cause, possibly
infective.’ (Bennett, 1955). Bennett also reported a high incidence of
‘stress diseases’ and history of stress-producing life situations, as well as
a ‘tense obsessional mental make-up’ among affected patients. Mau-
menee used fluorescein angioscopy to obtain fundamental information
regarding the pathophysiology of disease (Maumenee, 1965), finding
that the condition is associated with leakage at the level of the RPE, not
from the retinal vessels. The same group later suggested that a recently
invented device ‒ the laser ‒ might be used to treat this leak (Patz et al.,
1971). In a landmark paper, Gass outlined many of the modern ideas of
what he called idiopathic CSC (Gass, 1967), proposing that increased
permeability of the choriocapillaris causes increased hydrostatic pres-
sure in the choroid. This increased hydrostatic pressure in the choroid
and hyperpermeability of the choriocapillaris gives rise to pigment
epithelial detachments (PEDs) and defects in the RPE monolayer, al-
lowing fluid to leak under the neuroretina. This differs from neo-
vascularisation, in which PEDs occur due to leakage from newly formed
vessels. Although many alternate theories were proposed, the concept
of choroidal hyperpermeability was confirmed decades later with the
introduction of indocyanine green angiography (ICGA) and optical
coherence tomography (OCT) (Spaide et al., 1996b).
A population-based study in Olmsted County, MN, USA found that
the annual age-adjusted incidence of CSC from 1980 through 2002 was
9.9 and 1.7 per 100,000 in men and women, respectively, in a pre-
dominantly Caucasian population (Kitzmann et al., 2008). A more ba-
lanced sex-based distribution was found in a population-base study
from Taiwan, with an annual incidence of 54.5 men and 34.2 women
per 100,000 corticosteroid users (Tsai et al., 2014). A South Korean
cohort study of corticosteroid users and non-users found that the total
incidence of CSC was 5.4 men and 1.6 women per 10,000 person-years
(Rim et al., 2018). These discrepancies in the reported incidence of CSC
may be due to methodological and/or ethnic differences. Nevertheless,
the reported incidences may have been underestimated, as Kitzmann
et al. excluded patients without fluorescein angiography (FA) data, and
Tsai et al. and Rim et al. based their studies on insurance claims data
from nearly all nationwide claims submitted by healthcare providers in
Taiwan and South Korea, respectively. No significant differences in
incidence rates and disease spectrum have been reported in a retro-
spective analysis between 15 African American and 59 Caucasians CSC
patients (Desai et al., 2003). In Asians, however, pachychoroid disease
such as polypodal choroidal vasculopathy may be more prevalent than
in Caucasians (Cheung et al., 2018).
Multimodal imaging is essential in order to accurately diagnose
CSC. Using a combination of FA, ICGA, OCT, and fundus auto-
fluorescence (FAF) allows the practitioner to distinguish between CSC
and other conditions with overlapping clinical features. Using OCT, the
presence of SRF can be both assessed and quantified, which is generally
considered useful for estimating the episode duration and for de-
termining the subsequent treatment strategy (Song et al., 2012).
Moreover, FAF imaging can help estimate the duration of the CSC
episode and the damage induced by CSC, and can also help determine
the appropriate treatment strategy (Lee et al., 2016; Spaide and
Klancnik, 2005). The combination of OCT, FA, ICGA, and OCT angio-
graphy can be used to detect subretinal neovascularisation, which may
be challenging to conclusively confirm (Borrelli et al., 2018).
1.1. Clinical characteristics of CSC
Several subtypes of CSC have been proposed, but these are still
subject to debate, and there is currently no universally accepted clas-
sification system for CSC (Daruich et al., 2015; Nicholson et al., 2013;
Singh et al., 2018). This debate is based largely on the variable course
of the disease and discrepancies with respect to the classification of CSC
among ophthalmologists (Singh et al., 2018). Many authors use a basic
distinction between acute CSC (aCSC) and chronic CSC (cCSC) based on
the duration of SRF and the structural changes visible on multimodal
imaging (Cardillo Piccolino et al., 2005; Guyer et al., 1994).
Although the serous detachment in aCSC usually resolves within 3–4
months without the need for treatment, the detachment tends to persist
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in cCSC, and the chronic presence of SRF commonly leads to permanent
structural damage in the neuroretina and RPE, with irreversible long-
term vision loss (Laatikainen, 1994; Loo et al., 2002; Mrejen et al.,
2019; von Winning et al., 1982). In the aCSC/cCSC classification
system, aCSC usually presents with one ‒ or just a few ‒ focal leaks and
produces an isolated dome-shaped neuroretinal elevation (not to be
confused with a dome-shaped RPE-detachment), with few atrophic
changes in the RPE. In contrast, patients with cCSC can present with a
large number of leaks, and the chronic leakage of SRF tends to produce
a larger, less elevated neuroretinal detachment. However, some pa-
tients with CSC present with one or several leaks that last more than 4
months but are not associated with widespread RPE changes, a shallow
detachment, or decreased visual acuity. It is therefore debatable whe-
ther this clinical subgroup should be classified as aCSC or cCSC. Given
this wide clinical variability and overlap, progress towards a new
classification system has been slow; however, reaching a consensus
regarding the classification of CSC is an important first step towards
better defining the disease subgroups and treatment endpoints. The
subcategories that have been proposed include non-resolving CSC, re-
current CSC, and inactive CSC (Daruich et al., 2015), as well as severe
CSC based on multimodal imaging (Mohabati et al., 2018b, 2018c).
Patients with a single point of leakage are considered to have focal
leakage, whereas patients with several focal leakage points or ill-de-
fined areas of dye leakage on FA can be categorised as having diffuse
leakage (Gass, 1967). A focal leakage point on early FA typically in-
creases in size with indistinct borders in the late phase of FA due to the
leakage of fluorescein through the focal defect in the RPE. This focal
area often co-localises with a dome-shaped RPE detachment and is
presumed to be the point of least resistance at the RPE outer blood-
retina barrier due to damage by increased wall stress induced by an
increase in the vascular pressure gradient from the choriocapillaris. As a
result of this small tear in the RPE or focal outer blood-retina barrier
defect, fluid can flow from below the RPE into the subretinal space.
It is important to create at least a basic distinction between the
various clinical subtypes of CSC in order to define treatments, which
can be used in study designs. In this review, we use the basic distinction
between aCSC and cCSC, as this clinical distinction is the most widely
used in the context of the natural history and treatment of CSC.
1.1.1. Acute CSC
Acute CSC is defined as an acute-onset, dome-shaped serous de-
tachment of the neuroretina, with spontaneous complete resolution of
the resulting SRF in 3–6 months together with a good visual prognosis
(Daruich et al., 2015; Klein et al., 1974; Nicholson et al., 2013). Patients
with aCSC often present with altered vision and hypermetropisation
(Daruich et al., 2017). In a study involving 27 patients with CSC with an
average follow-up of 23 months, SRF spontaneously resolved in all 27
patients within an average duration of follow-up of 3 months (Klein
et al., 1974). In another study of 31 patients with aCSC, SRF completely
resolved by 6 months of follow-up in 84% of patients (Daruich et al.,
2017). However, SRF has been reported to recur in up to 52% of pa-
tients (Ficker et al., 1988; Fok et al., 2011; Yap and Robertson, 1996).
More importantly, even in patients who had SRF for only a short period
of time, CSC can lead to irreversible damage to photoreceptors; thus,
treatment may also be indicated in aCSC cases (Baran et al., 2005;
Behnia et al., 2013; Hata et al., 2013). Interestingly, some patients self-
describe their disease duration as lasting only a few days, whereas
fundus imaging may reveal evidence of prolonged disease; patient-re-
ported disease duration may therefore be considered unreliable (Ooto
et al., 2010a). Most studies reporting the spontaneous course of CSC
were published before the availability of OCT, meaning that residual
shallow detachments were difficult ‒ or impossible ‒ to identify at that
time (Wang et al., 1999). Several risk factors for prolonged CSC dura-
tion have been identified at presentation, which may influence the
decision regarding whether or not to treat. These risk factors include
subfoveal choroidal thickness> 500 μm, PED height> 50 μm,
presentation at 40 years of age or older (Daruich et al., 2017), and
photoreceptor atrophy of the detached retina together with granular
debris in the SRF on OCT (Wang et al., 2005). Patients who present with
aCSC with large amounts of SRF may be more prone to photoreceptor
loss compared to patients who present with relatively small amounts of
SRF (Gerendas et al., 2018; Nair et al., 2012).
In aCSC, 1–3 focal leakage points are typically visible on FA. The
classic features of aCSC on FA include a pinpoint hyperfluorescent RPE
defect with an ascending area of hyperfluorescence over time, com-
monly referred to as a ‘smoke stack leakage’ (Fig. 1B, D, F). This pattern
of leakage can be caused by a mechanical disruption in the RPE with
choroidal heat patterns and molecular differences between the fluor-
escein dye and the fluorescein albumin conjugate, combined with
gravitational forces that give rise to this characteristic pattern of
fluorescein dye in the subretinal space. More commonly, an ‘ink-blot’
pattern of leakage occurs, in which the focal leak that appears during
dye transit becomes poorly defined, as the dye leaks more slowly into
the subretinal space through the RPE defect (Wang et al., 2008). Pa-
tients who present with a smoke stack leakage on FA may have a larger
serous detachment compared to patients with an ink-blot leakage
(Friberg and Campagna, 1989), which can result in increased meta-
morphopsia. The location of the focal leakage point is usually corre-
lated with a micro-tear in the RPE (Yannuzzi et al., 2015). In aCSC,
these defects occur in the absence of diffuse atrophic changes in the RPE
(Daruich et al., 2015). In areas in which FA shows focal leakage, ICGA
can reveal areas of choroidal vascular hyperpermeability, possibly
Fig. 1. Multimodal imaging of a 34-year-old male patient diagnosed with acute
central serous chorioretinopathy (A–I). The presence of foveal subretinal fluid
overlying a thick choroid (526 μm) with pachyvessels (white arrows) can be
detected on optical coherence tomography (OCT, A). On fluorescein angio-
graphy there is a focal area of hyperfluorescent dye leakage, which increases
and ascends in the subretinal space to produce a ‘smoke stack’ leakage pattern
with additional hyperfluorescent areas of choroidal vascular hyperpermeability
(white arrows, B, D, F). On indocyanine green angiography there is a similar
leakage pattern with additional hyperfluorescent areas of choroidal vascular
hyperpermeability (G). The serous detachment seen on OCT (A) and colour
fundus photography (H) has a hyperautofluorescent border on fundus auto-
fluorescence (I).
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depending on whether the pore size is large enough to allow the escape
of indocyanine green‒bound plasma proteins. On the other hand,
choroidal hyperpermeability does not always correspond to the hy-
perfluorescent area on FA (Yannuzzi et al., 2003). Indeed, the hyper-
fluorescent areas seen on ICGA are often more extensive than the hy-
perfluorescent areas on FA (Fig. 1B–G), which is believed to be due to
the higher permeability of large choroidal vessels (Scheider et al., 1993;
Spaide et al., 1996b). Hypo-autofluorescent abnormalities on FAF have
also been found to correlate with areas of leakage on FA (Eandi et al.,
2005), which may indicate the involvement of the RPE in the patho-
physiology of CSC, as FAF reflects the structural and functional status of
the RPE (Freund et al., 2013).
The volume of SRF can be quantified using OCT, and higher SRF
volume may be associated with poorer best-corrected visual acuity
(BCVA) (Nair et al., 2012). The presence of subretinal hyperreflective
dots on OCT ‒ which may represent macrophages that contain phago-
cytosed outer segments ‒ can migrate progressively into the neuror-
etina in patients with a prolonged disease course (Spaide and Klancnik,
2005). However, subretinal hyperreflective dots can also represent
plasma proteins from the choriocapillaris and inflammatory debris
(Wang et al., 2005). OCT can reveal fibrin clots that result from fi-
brinogen leaking through a defect in the RPE (Yu et al., 2014). Al-
though changes in choroidal haemodynamics have been observed in
aCSC using laser speckle flowgraphy (Saito et al., 2015), subfoveal
choroidal thickness does not appear to be correlated with the amount of
SRF (Goktas, 2014). In contrast, SRF resolution and BCVA in patients
with aCSC appear to be related to macular choroidal blood flow velo-
city, with flow velocity decreasing as aCSC resolves (Saito et al., 2013).
Non-resolving CSC has been described as a variant of aCSC in which
SRF persists for more than 4 months without atrophic RPE abnormal-
ities (Daruich et al., 2015). Moreover, recurrent CSC has been defined
as an aCSC episode followed by one or more episodes after complete
SRF resolution (Daruich et al., 2015).
1.1.2. Chronic CSC
Chronic CSC is characterised by serous detachment of the retina,
with either small or more extensive areas of serous detachment of the
RPE, together with atrophic changes to the outer retina and RPE de-
veloping secondary to choroidal vasculopathy. On FA, one or more
focal leakage points can be visible (Fig. 2B, D, F); alternatively, distinct
points of leakage can be absent or difficult to identify against a back-
ground of irregular RPE translucency. Patients with cCSC typically have
persistent serous detachment(s) on OCT for longer than 4–6 months
(Daruich et al., 2015). Eyes with cCSC often have widespread ICGA
abnormalities (Fig. 2G), including delayed choroidal filling, dilated
choroidal veins, and/or choroidal vascular hyperpermeability (Pang
et al., 2014). Relatively few patients with cCSC have a history of aCSC,
which may indicate significant clinical differences between aCSC and
cCSC. Interestingly, however, aCSC and cCSC share several genetic risk
factors (Jalkh et al., 1984; Mohabati et al., 2018, 2018c; Otsuka et al.,
2002; Yannuzzi et al., 1984) and possible pathophysiological overlap,
particularly given similarities with respect to multimodal imaging
(Imamura et al., 2009). In this respect, it is interesting to note that a
retrospective study found that 50% of unspecified CSC patients devel-
oped atrophic changes in the RPE within 12 years of presentation
(Castro-Correia et al., 1992). No marked clinical differences have been
reported between cCSC patients with focal leakage and those diffuse
leakage on FA, which may indicate that the choroid is the primary in-
volved structure both in cCSC patients with focal and with diffuse
leakage (van Rijssen et al., 2019b).
Diffuse atrophic changes in the RPE and atrophic tracts may be the
result of previous CSC episodes and the prolonged presence of SRF
under the serous neuroretinal detachment, or it may be the result of an
underlying choroidal dysfunction that directly affects the RPE, for ex-
ample as seen in pachychoroid pigment epitheliopathy (Cheung et al.,
2018; Mohabati et al., 2018b, 2018c) (Fig. 2). The term gravitational
tract is used to describe areas of RPE and photoreceptor outer segment
atrophy, hyperfluorescence on FA, and mixed hyperautofluorescent and
hypo-autofluorescent changes on FAF, which extend inferiorly of the
prominent points of leakage. These tracts occur passively due to pro-
longed leakage and should not necessarily be targeted for treatment.
The location of the accumulated SRF may be linked to the hyper-
fluorescent area on OCT (Montero and Ruiz-Moreno, 2005), and gran-
ular hypo-autofluorescence due to RPE atrophy may be present on FAF
(Lee et al., 2016). The progression of the autofluorescence patterns in
cCSC is slow, taking an average of 24 months for the granular hypo-
autofluorescent changes to progress to a confluent pattern of hypo-au-
tofluorescence (Zola et al., 2018a). When outer segment debris persists
in the subretinal space, it becomes increasingly hyperautofluorescent
(Spaide, 2008). In cases of cCSC with more marked and/or extensive
atrophic changes in the RPE, patients often do not present with a dome-
shaped PED (as in aCSC); rather, these patients present with a shallow,
broader PED that ‒ in some cases ‒ can have an underlying neovascular
component (Fig. 3). This neovascular component should be suspected in
cases in which the space between the shallow PED and Bruch's mem-
brane on OCT contains mid-reflective ‒ presumably neovascular –
material rather than being hyporeflective (Fig. 3A), which is more
suggestive of sub-RPE fluid (Fig. 2). En face swept-source OCT and OCT
angiography can be useful in identifying choroidal neovascularisation
(CNV) without the use of conventional angiography (Fig. 3A, G) (de
Carlo et al., 2015; Ferrara et al., 2014; Soomro and Talks, 2018).
Fig. 2. Multimodal imaging of a 44-year old man with chronic central serous
chorioretinopathy (A–G). Subretinal fluid, photoreceptor outer segment
atrophy, a small retinal pigment epithelial detachment (black arrow), choroidal
thickening, and dilated veins in Haller's layer (white arrow) are present on
optical coherence tomography (A). Focal areas of hyperfluorescent leakage
(white arrows) are seen at 1 min (B), 3 min (D), and 6min (F) fluorescein an-
giography. Dilated choroidal vessels and choroidal vascular hyperpermeability
(G, white arrow) are present on indocyanine green angiography (C, E, G).
Colour fundus photography shows pigmentary abnormalities, some of which
correspond to the areas of leakage seen on fluorescein angiography (H). Fundus
autofluorescence shows mostly hyperautofluorescent abnormalities, which re-
present the retinal pigment epithelium atrophy track induced by chronic sub-
retinal fluid (I).
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Some cases of cCSC can be complicated by the accumulation of
cystoid fluid, giving rise to a complication called posterior cystoid
retinal degeneration (PCRD), in which the cystoid changes do not ne-
cessarily involve the central macula, as they are typically extrafoveal at
various locations in the posterior pole (Fig. 4E-H) (Cardillo Piccolino
et al., 2008a; Mohabati et al., 2018c). Importantly, PCRD has been
reported to cause a severe loss of central vision in some cases of CSC
(Iida et al., 2003). The cystoid intraretinal spaces can be seen on OCT,
but unlike typical cystoid macular oedema they do not stain on FA.
PCRD is associated with cCSC symptoms that persist longer than 5 years
(Cardillo Piccolino et al., 2008b). Foveal damage and vision loss can
occur due to the intraretinal fluid itself, as well as the associated foveal
detachment. In a study of 34 eyes with cCSC and PCRD, Cardillo Pic-
colino and colleagues found that visual acuity ranged from 20/20 to
20/400, with visual acuity of 20/40 or better in eyes in which the in-
traretinal fluid spared the foveal centre (Cardillo Piccolino et al.,
2008a). Using OCT angiography, Sahoo and colleagues detected CNV in
nearly half of the cases (13 out of 29 eyes) with cystoid macular de-
generation (Sahoo et al., 2019). Patients with cCSC often experience a
gradual decline in BCVA and contrast sensitivity due to damage to
Fig. 3. Imaging of a 59-year-old man with chronic central serous chorior-
etinopathy complicated by an occult neovascular membrane. The left eye (A–G)
and right eye (H–K) are depicted. Retinal pigment epithelium alterations on
fundus photography, accompanied by foveal subretinal fluid and a relatively
flat, irregular retinal pigment epithelial detachment (PED) on optical coherence
tomography can be observed (OCT, A). The space below the PED and above
Bruch's membrane shows some greyish reflectivity, which could be suggestive
of neovascular tissue. Leakage of fluorescein and diffuse retinal pigment epi-
thelium alterations are present on fluorescein angiography (B, D). Indocyanine
green angiography (ICGA) shows large hyperfluorescent areas suggestive of
choroidal hyperpermeability (C, E), and a smaller macular area with a certain
degree of demarcation that is suggestive of a neovascular membrane (deli-
neated by three arrows in C and E). The optical coherence tomography an-
giogram of the superficial capillary plexus has a relatively normal appearance
(F), but a neovascular network is clearly visible when segmentation is adjusted
to cover the space between the retinal pigment epithelium and Bruch's mem-
brane (G). In the fellow (right) eye, an extrafoveal, small dome-shaped PED
with an attached small, flat PED with surrounding subretinal fluid is seen on
OCT (arrow in H); which corresponds with an area of hyperfluorescence on
ICGA (J). However, OCT angiography segmented for this area between the PED
and Bruch's membrane does not show signs of neovascularisation (K).
Fig. 4. Imaging of a 32-year-old man diagnosed with acute-onset central serous
chorioretinopathy (A–D). Yellow-white subretinal fibrin can be observed on
fundus photography (A), which is hyperreflective on optical coherence tomo-
graphy (OCT) (D), with a roughly vertical sausage-shaped clear area (arrow in
A), which corresponds to a small round hyporeflective zone on OCT (white
arrow in D). This clear zone within the lesion on fundoscopy and hyporeflective
zone on OCT most likely corresponds to the upward leakage track originating
from the focal leakage point on fluorescein angiography (right arrow in B). In
addition, some mildly atrophic retinal pigment epithelial changes in the tem-
poral macula (left arrow in B) also indicate a certain degree of advanced/
chronic disease.
Multimodal imaging of a 46-year-old man with chronic central serous chor-
ioretinopathy with posterior cystoid retinal degeneration (E-H). Multiple
leakage points are visible on fluorescein angiography (F), along with hyper-
fluorescence on indocyanine green angiography (G). Posterior cystoid retinal
degeneration is visible in in E and H (at the location of the arrows). (For in-
terpretation of the references to colour in this figure legend, the reader is re-
ferred to the Web version of this article.)
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macular photoreceptors (Breukink et al., 2017; Cardillo Piccolino et al.,
2005; Ooto et al., 2010b; Spaide et al., 1996a); approximately 13% of
these eyes progress to legal blindness, reaching a BCVA of 20/200 or
worse after 10 years (Mrejen et al., 2019). This marked loss of visual
acuity can be due to atrophic RPE changes at the central fovea together
with photoreceptor damage, cystoid macular degeneration, and/or
secondary CNV. Descending tracts are more frequent in cCSC compared
to aCSC (Imamura et al., 2011). Although visual symptoms in cCSC
usually present in only one eye, up to 42% of patients with cCSC show
signs of bilateral abnormalities on FA (Gackle et al., 1998; Levine et al.,
1989). Bilateral CSC is relatively more common in patients of 50 years
or older, with a prevalence of 50% in this age group compared to 28%
in patients under the age of 50 (Spaide et al., 1996a). Moreover, bi-
lateral disease activity together with bilateral SRF accumulation is more
common in cases with severe cCSC, affecting up to 84% of these pa-
tients (Mohabati et al., 2018c; Otsuka et al., 2002). These patients with
bilateral severe cCSC are highly prone to develop severe visual im-
pairment (Mohabati et al., 2018c; Mrejen et al., 2019). A rare yet severe
manifestation of cCSC caused by many vigorous leaks is bullous retinal
detachment, which commonly presents with the significant accumula-
tion of subretinal fibrin. In some cases, bullous retinal detachment is
accompanied by complete disruption of the edges of a PED, thereby
producing an avulsion (i.e. rip or tear) in the RPE (Balaratnasingam
et al., 2016).
1.2. Risk factors for developing CSC
On average, men are 2.7–8 times more likely to develop CSC com-
pared to women (Haimovici et al., 2004; Tittl et al., 1999, 2003). The
most important external risk factor for developing CSC is corticosteroid
use, with an associated odds ratio of up to 37 to 1 (Haimovici et al.,
2004). However, the precise effect of corticosteroid use on CSC risk is
unclear, as lower odds ratios ‒ in some cases, corresponding with only a
slightly increased risk ‒ have been reported in patients who use corti-
costeroids (Carvalho-Recchia et al., 2002; Rim et al., 2018; Tsai et al.,
2014). An increase in choroidal thickness and features of CSC have been
reported in 1 out of 18 patients after high-dose corticosteroid treatment
(Han et al., 2014). In rare cases, even minimal exposure to corticos-
teroids via intranasal, inhalation, or extraocular application has been
associated with an increased risk of CSC (Carvalho-Recchia et al., 2002;
Haimovici et al., 1997). In 1987, Yannuzzi reported an association
between CSC and type A behaviour, which has personality traits that
include an intense, sustained drive to achieve self-selected goals and an
eagerness to compete, along with a desire for recognition and ad-
vancement (Yannuzzi, 1987). Additional components that have been
reported as being part of the ‘CSC patient profile’ include impulsiveness,
a drive to overachieve, emotional instability, and hard-driving com-
petitiveness, all of which have been hypothesised to affect the risk of
CSC (Conrad et al., 2014). A stressful life event, shift work, poor sleep
quality, and disturbances in the circadian rhythm have also been as-
sociated with an increased risk of CSC (Bousquet et al., 2016; Gelber
and Schatz, 1987; Ji et al., 2018; Setrouk et al., 2016). Interestingly,
individuals with type A behaviour are believed to have increased levels
of corticosteroids and catecholamines (Williams et al., 1982), which
may underlie their potentially increased risk of developing CSC.
Moreover, many studies described an association between CSC risk and
both stress and certain personality traits (Fok et al., 2011; Kim et al.,
2018b; Lahousen et al., 2016; Matet et al., 2018). In contrast, a recent
study involving 86 patients with cCSC found that the prevalence of
maladaptive personality traits was similar between patients and a re-
ference population (van Haalen et al., 2018). Various coping strategies
have also been associated with CSC (Lahousen et al., 2016; van Haalen
et al., 2018), and elevated psychological stress has been reported in CSC
patients within a few weeks following the onset of ocular symptoms
(Spahn et al., 2003). Moreover, psychosocial status has been correlated
to the phase and subtype of CSC (Kim et al., 2018b), with CSC patients
having a lower quality of life, more psychological problems, and higher
anxiety compared to healthy controls (Bazzazi et al., 2015; Sahin et al.,
2014). A history of psychiatric illness has also been associated with an
increased risk of recurrence in CSC cases (Fok et al., 2011). Never-
theless, quantifying and qualifying stress ‒ and its association with CSC
‒ will likely require large systematic studies including detailed psy-
chometric assessments using suitable, validated questionnaires.
Endogenous hypercortisolism (i.e. Cushing's syndrome) has also
been reported to increase the risk of developing CSC (Abalem et al.,
2016; Bouzas et al., 1993; Carvalho-Recchia et al., 2002; Garg et al.,
1997). In addition, several studies found increased levels of cortisol in
the serum of patients with CSC patients, albeit without meeting the
diagnostic criteria for Cushing's syndrome (Haimovici et al., 2003;
Kapetanios et al., 1998; Zakir et al., 2009). CSC can be a presenting
symptom in Cushing's syndrome, and SRF was reported to resolve in
patients following surgery for treating Cushing's syndrome (van Dijk
et al., 2016). In their endocrinological work-up of 86 patients with
cCSC, Van Haalen and colleagues found elevated 24-h urinary free
cortisol levels, indicating increased activity of the hypothalamic-pitui-
tary-adrenal axis (van Haalen et al., 2018b); however, none of the pa-
tients in their study met either the clinical or biochemical criteria for
Cushing's syndrome (van Haalen et al., 2018b). Pregnancy has also
been associated with an increased risk of CSC along with hypertensive
and vascular disorders (Sunness, 1988). This increased risk of CSC
during pregnancy may be caused by hormonal changes that can induce
vascular changes in the choroid. Although choroidal thickness does not
appear to change during a healthy pregnancy, choroidal thickness can
be increased in preeclampsia, and associated hypertension may also
affect choroidal circulation (Kim et al., 2016). Choroidal hyperperme-
ability and stasis in the choroidal vessels, which may occur during
preeclampsia, may also play a role in the development of CSC during
pregnancy.
Patients in need of treatment with mitogen-activated protein kinase
(MEK) inhibitors may develop a serous retinal detachment due to
toxicity or autoantibodies (Urner-Bloch et al., 2014; van Dijk et al.,
2015). These cases have been referred to as MEK inhibitor associated
serous retinopathy (MEKAR). In contrast to CSC, no choroidal hy-
perpermeability is visible on ICGA in these patients, there is no increase
in choroidal thickness, and no PEDs or focal leakage on FA are present
(Francis et al., 2017; van Dijk et al., 2015). Between 20 and 65% of
patients treated with MEK inhibitors may develop a serous retinopathy,
with only a minority of these patients developing mild symptoms,
which are usually transient, so discontinuation of this treatment for this
reason is generally not required (Urner-Bloch et al., 2014; van Dijk
et al., 2015).
Other risk factors associated with CSC include gastro-oesophageal
disorders such as Helicobacter pylori infection, uncontrolled systemic
hypertension, antibiotics, alcohol, allergic respiratory disease, high
socioeconomic status, alcohol consumption, smoking, coronary heart
disease, obstructive sleep apnoea, poor sleep quality, autoimmune
disease, and hyperopia; in contrast, myopia was found to protect from
CSC (Bagheri et al., 2017; Chatziralli et al., 2017; Daruich et al., 2015;
Eom et al., 2012; Haimovici et al., 2004; Ji et al., 2018; Manayath et al.,
2016; Matet et al., 2018; Tittl et al., 1999; Yavas et al., 2014). With
respect to cardiovascular disease, the pathogenic mechanism for CSC
may lie in general endothelial cell dysfunction (Wang et al., 2017).
Some studies reported a familial predisposition for CSC, which
suggests that CSC may have a genetic component (Lin et al., 2000; van
Dijk et al., 2019; Weenink et al., 2001). Recently, several single nu-
cleotide polymorphisms (SNPs) were associated with an increased risk
of CSC. Some of these SNPs are located in genes involved in the com-
plement system, including CFH, which encodes complement factor H
(de Jong et al., 2015; Hosoda et al., 2018; Miki et al., 2014; Schellevis
et al., 2018), the C4B, which encodes complement factor 4B (Breukink
et al., 2015), and the NR3C2 gene, which encodes nuclear receptor
subfamily 3 group C member 2, a mineralocorticoid receptor (MR) (van
T.J. van Rijssen, et al. Progress in Retinal and Eye Research 73 (2019) 100770
6
Dijk et al., 2017b). In addition, CSC has been associated with the genes
that encode age-related macular degeneration susceptibility 2 (ARMS2)
(de Jong et al., 2015), cadherin 5 (CDH5) (Schubert et al., 2014), va-
soactive intestinal peptide receptor 2 (VIPR2) (Hosoda et al., 2018), and
solute carrier family 7 member 5 (SLC7A5) (Miki et al., 2018; Moschos
et al., 2016). Interestingly, a familial form of pachychoroid, possibly
with an autosomal dominant inheritance pattern, has also been de-
scribed (Lehmann et al., 2015), as well as an association with variants
in the CFH and VIPR2 genes in an Asian cohort (Hosoda et al., 2018).
For a more detailed discussion regarding this topic, the reader is re-
ferred to Kaye et al. Progress in Retinal and eye Research 2019.
1.2.1. Risk of recurrence and disease progression
If untreated, 43–51% of patients with aCSC experience at least one
recurrence (Ficker et al., 1988; Matet et al., 2018; Ozkaya et al., 2016;
Yap and Robertson, 1996). In patients with untreated cCSC, the re-
ported 1-year recurrence rate is 30–52% (Fok et al., 2011; Gilbert et al.,
1984). Several risk factors have been identified for CSC recurrence and
disease progression, including the use of corticosteroids, untreated
hypertension, a thick subfoveal choroid, non-intense hyperfluorescence
on FA, and shift work (Haimovici et al., 2004; Matet et al., 2018).
Moreover, depression and anxiety disorders have been associated with
an increased risk of recurrence in both aCSC and cCSC (Fok et al.,
2011). Severe cCSC tends to be progressive, although treatment can
slow the disease's progression and stabilise BCVA (Mohabati et al.,
2018c; Otsuka et al., 2002). Interestingly, few patients who present
with cCSC have a history of aCSC, which may indicate that in addition
to having a different visual prognosis, different underlying disease
mechanisms are likely involved in the aetiology and progression of the
acute and chronic forms of the disease (Mohabati et al., 2018c).
1.3. Pathophysiology
1.3.1. Choroidal dysfunction
Based on clinical evidence and FA findings, Gass suggested back in
1967 that hyperpermeability and increased hydrostatic pressure in the
choroid may induce damage to the RPE, subsequently giving rise to
either a PED or SRF leakage through a defect in the RPE outer blood-
retina barrier (Gass, 1967). The presence of choroidal hyper-
fluorescence on ICGA supports the hypothesis that choroidal dysfunc-
tion is the primary underlying pathogenic mechanism in CSC (Hayashi
et al., 1986; Spaide et al., 1996b). Other changes in the choroid further
support the notion that abnormalities in choroidal structure and func-
tion play a fundamental role in the development of CSC; these changes
include increased choroidal thickness (Imamura et al., 2009), which
can decrease after treatment (Maruko et al., 2010), dilated veins in the
Haller layer, atrophy of inner choroidal layers, increased choroidal
vascularity index (Agrawal et al., 2016), and dysregulation of choroidal
blood flow (Cardillo Piccolino et al., 2018) (Figs. 1A and 2F and G).
Pathological processes that contribute to the observed choroidal ab-
normalities can include choroidal stasis, ischaemia, autonomic dysre-
gulation, inflammation, and abnormalities in the complement system
(Gass, 1967; Schellevis et al., 2018). However, classic inflammation
within the choroid does not likely play a role in CSC, as corticosteroids
can induce or worsen the disease. The above-mentioned pathological
processes can lead to damage of the RPE outer blood-retina barrier and
RPE alterations including serous PED, hyperplasia, and atrophy, which
can be detected on FA and FAF (Daruich et al., 2015; Levine et al.,
1989; Spaide and Klancnik, 2005). This hypothesis is supported by
findings on OCT angiography, including increased signal intensity and
thicker choriocapillaris vasculature (Chan et al., 2016). The choroidal
thickness has been reported to vary over the day, which may lead to
diurnal fluctuations in the amount of SRF that is present in CSC (Brown
et al., 2009; Siegfried et al., 2019). Choriocapillary hypoperfusion has
also been detected on OCT angiography in CSC cases, and this reduced
perfusion may result in ischaemia in adjacent retinal tissues due to
insufficient oxygen delivery (Gal-Or et al., 2018; Rochepeau et al.,
2018). This focal choriocapillary ischaemia ‒ combined with adjacent
hyperperfusion ‒ can result in SRF leakage (Teussink et al., 2015).
Choroidal vascular dysfunction is a key feature in theories explaining
the pathophysiology of CSC, with RPE alterations being secondary to
choroidal changes (Nicholson et al., 2013).
1.3.2. Retinal pigment epithelium (RPE) dysfunction
The RPE plays an important role in the pathophysiology of CSC
(Marmor, 1988; Spitznas, 1986). Focal areas of leakage through RPE
were hypothesised to underlie the accumulation of SRF in a study by
Negi and Marmor who suggested that defects in the RPE lead to an
outflow of SRF to the choroid (Negi and Marmor, 1984). However, as
described in section 1.3.1, there is overwhelming evidence that defects
in the RPE are presumably secondary to choroidal dysfunction, as the
choroidal abnormalities are more extensive than ‒ or at least as ex-
tensive as ‒ the RPE abnormalities (Spaide et al., 1996b), and choroidal
dysfunction has been well-described using ICGA, structural OCT, and
OCT angiography (Spaide et al., 1996b; Teussink et al., 2015). Inter-
estingly, RPE abnormalities can also be present in the unaffected eye in
patients with unilateral CSC, despite an absence of SRF (Gupta et al.,
2010; Warrow et al., 2013). Atrophy of the RPE is associated with a
reduced choroidal permeability, seen as hypofluorescence on ICGA
(Spaide et al., 1996b). This can be the result of progressive quiescence
of the choriocapillaris after a long-lasting disease and chronic RPE
atrophy, as the secretion of vascular endothelial growth factor (VEGF)
from the RPE is required in order to maintain the normal structure and
homeostasis of the choriocapillaris (Bhutto and Lutty, 2012). The re-
sulting increased hydrostatic pressure in the choroid may lead to re-
duced RPE barrier function, resulting in an accumulation of SRF (Gass,
1967). This hypothesis is supported by findings following photo-
dynamic therapy (PDT), measured using both ICGA and enhanced
depth imaging OCT (Maruko et al., 2010; Yannuzzi et al., 2003). Ap-
parently, secondary damage to the RPE can range from small focal le-
sions to extensive degeneration, which is sometimes referred to as ei-
ther diffuse retinal pigment epitheliopathy or diffuse atrophic RPE
alterations (Mohabati et al., 2018c; Polak et al., 1995; von Winning
et al., 1982; Yannuzzi et al., 1984). An alternative theory to explain the
pathogenesis of CSC posits that a focal loss of polarity of the RPE cells
induces the active transport of SRF to the subretinal space (Spitznas,
1986).
1.3.3. Pachychoroid disease
CSC is considered part of the pachychoroid disease spectrum
(Cheung et al., 2018). This spectrum encompasses several disease en-
tities, all of which have common features that include a diffuse or focal
increase in choroidal thickness, atrophy of the inner choroidal layers,
dilated outer choroidal veins (i.e. ‘pachyvessels’), and choroidal vas-
cular hyperpermeability on ICGA (Cheung et al., 2018). According to
the pachychoroid disease hypothesis, disease progression (or regres-
sion) can occur in multiple stages, yet many patients presumably never
progress from the earlier stages to symptomatic advanced disease with
visual impairment. In the earliest stage of the disease, uncomplicated
pachychoroid, choroidal changes, and thickening of the choroid are
present without visible RPE and/or neuroretinal changes, but the pa-
tient does not present with visual symptoms. In the second stage, re-
ferred to as pachychoroid pigment epitheliopathy, mild changes in the
RPE appear (Warrow et al., 2013). In the third stage of pachychoroid
disease progression, CSC (which itself encompasses its own disease
spectrum, as discussed above), SRF leakage causes serous neuroretinal
detachment, presumably resulting from an acutely or chronically dys-
functional outer blood-retina barrier due to underlying choroidal
thickening, congestion, and dysfunction. The fourth stage in the pa-
chychoroid spectrum is pachychoroid neovasculopathy, which can in-
clude a polypoidal vasculopathy component (Fig. 3) (Fung et al., 2012).
Patients with pachychoroid neovasculopathy ‒ either with or without a
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polypoidal component ‒ can present with serous SRF without having a
history of CSC.
It should be noted the term ‘pachychoroid’ literally means ‘thick-
ened choroid’, and is therefore rather non-specific. Whether or not a
choroid can be considered thickened is subject to debate and can de-
pend strongly on a variety of factors such as refractive error, associated
axial length, and time of day (Brown et al., 2009; Ikuno et al., 2010).
Many patients with a relatively thickened choroid will never develop
clinically relevant abnormalities such as pachychoroid pigment epi-
theliopathy or CSC. Conversely, some patients develop typical CSC
despite having choroidal thickness within the normal range. Most CSC
patients, however, have a significantly increased choroidal thickness in
the affected eye, with only 5 out of 28 unspecified CSC eyes in a ret-
rospective study having a choroidal thickness below 400 μm (Cheung
et al., 2018; Imamura et al., 2009). Pachychoroid is associated with
hyperopia, and CSC is extremely rare in myopic patients (Ersoz et al.,
2018; Manayath et al., 2016); however, typical CSC can still also occur
in emmetropic ‒ and even myopic ‒ patients with choroidal thickness
within the ‘normal’ range, if the choroid is relatively thickened and
dysfunctional. Therefore, a thickened (or relatively thickened) choroid
is an important risk factor for CSC, but the actual dysfunctional, con-
gestive, ‘leaky’ properties of such a choroid may be at least as important
in the actual disease progression within the pachychoroid spectrum.
1.4. Differential diagnosis
The differential diagnosis for CSC encompasses a broad range of
disease categories that should be taken into account when confronted
with serous neuroretinal detachment or a clinical picture suggestive of
such a detachment. The most common diseases in the differential di-
agnosis of CSC include diseases associated with macular neovascular-
isation, such as AMD and polypoidal choroidal vasculopathy. In order
to differentiate between these diseases and CSC, one should obtain
OCT, OCT angiography, FA, and ICGA imaging. Retinal drusen are a
distinctive feature of AMD, while polypoidal lesions on OCT, OCT an-
giography, FA, and especially ICGA are typical for polypoidal choroidal
vasculopathy. Other diseases in the differential diagnosis of CSC include
inflammatory ocular diseases, ocular tumours, haematological diseases,
genetic retinal diseases, ocular developmental anomalies, and medica-
tion-induced disease. An overview of these diseases is given in Table 1.
An in-depth discussion of these differential diagnoses is beyond the
scope of this review; therefore, the reader is referred to Kaye et al.
Progress in Retinal and Eye Research 2019.
2. Treatments for CSC
Defining an optimal treatment for CSC is complicated by the broad
range of disease presentations and clinical course, as well as the poorly
understood pathophysiology of CSC, and lack of consensus on a clas-
sification system (Mehta et al., 2017; Singh et al., 2018). Because of the
relatively favourable visual prognosis for patients with CSC, the pre-
ferred treatment modalities should have a favourable safety profile.
Most studies published to date analysed retrospective data and varied
with respect to their inclusion and exclusion criteria, clinical defini-
tions, and study endpoints (van Rijssen et al., 2018a). The only large,
prospective multicentre randomised controlled treatment trial for the
treatment of cCSC conducted to date is the PLACE trial (van Dijk et al.,
2018b). This trial compared differences in percentage of patients with
complete resolution of SRF, BCVA, retinal sensitivity on micro-
perimetry, and in the 25-item National Eye Institute Visual Function
Questionnaire (NEI-VFQ-25) score between cCSC patients treated with
either half-dose PDT or HSML. Additional large, prospective, rando-
mised controlled trials performed over a defined treatment period are
particularly important for CSC, given the relatively high likelihood of
either spontaneous improvement or resolution of the serous neuror-
etinal detachment. If the study design is not appropriate ‒ in particular,
lacking a suitable control group ‒ spontaneous improvement may cause
the researcher to erroneously conclude that the treatment was effective.
Given the range of interventions used for treating CSC (discussed in
detail below), it should be obvious that the high rate of spontaneous
improvement in CSC may explain the fact that non-systematic, non-
prospective, non-randomised testing of a wide range of interventions
has yielded many promising findings that have never been replicated
satisfactorily.
2.1. Aims of treatment
The aim of treatment for CSC is to preserve the outer neurosensory
retinal layers and achieve complete resolution of the serous neuror-
etinal detachment and the underlying SRF, as even a small amount of
remaining SRF can lead to irreversible damage to the photoreceptors
(Haga et al., 2017; Loo et al., 2002; van Rijssen et al., 2018a). It is
therefore commonly accepted that complete elimination of SRF, in
order to restore normal anatomical and functional photoreceptor-RPE
interaction, should be the principal surrogate endpoint in intervention
trials regarding CSC. Following restoration of the photoreceptor-RPE
anatomy, visual symptoms usually decrease gradually and BCVA im-
proves (van Rijssen et al., 2018a). Even with anatomically successful
treatment, the persistence of visual sequelae due to pre-existing irre-
versible retinal damage is relatively common; therefore, a meticulous
clinical history should be obtained from the patient prior to treatment
(Wong et al., 2004). These persistent visual symptoms can include
suboptimal visual acuity, metamorphopsia, and loss of contrast and/or
colour vision. Another important aim of treatment is to prevent re-
currences and subsequent disease progression.
Although an important question is whether the risk of recurrence is
associated with any particular treatment(s), insufficient evidence is
currently available. In aCSC, which has a relatively high rate of spon-
taneous resolution, an effective treatment should ideally prevent re-
currences and subsequent disease progression. In cCSC, the primary aim
of treatment is currently to achieve ‒ and maintain ‒ the complete
resolution of SRF and intraretinal fluid (if present). In addition, other
factors such as subjective symptoms, the patient's age, and the patient's
professional dependence on high visual acuity, may be taken into ac-
count. Young patients with CSC generally have a higher cumulative
lifetime risk of recurrence compared to older patients, given their
longer life expectancy. On the other hand, older patients with CSC have
a higher risk of developing neovascularisation and/or polypoidal
choroidal vasculopathy.
While complete resolution of SRF should be the principal surrogate
endpoint for trials on CSC, this may not be the case in AMD patients
with accompanying SRF. In AMD patients with SRF, the BCVA may be
relatively preserved and complete resolution of the SRF may not be
required to still maintain a relatively favourable BCVA (Dadgostar
et al., 2009; Jang et al., 2015). However, CSC and AMD are different
disease entities with potentially different types of and rates of leakage
and a different composition of the SRF. Prolonged SRF can lead to ir-
reversible damage to the photoreceptors (Loo et al., 2002), and a sub-
group of cCSC patients can still have a significantly affected vision-re-
lated quality of life due to vision loss in progressive disease (Breukink
et al., 2017), and may even become legally blind (Mrejen et al., 2019).
2.2. Elimination of risk factors
Regardless of the subtype of CSC, it is important to identify whether
the use of corticosteroids or the presence of other risk factors is asso-
ciated with CSC. Thus, patients may be advised to discontinue the use of
all forms of corticosteroids (including topical and inhaled medication)
provided that their general health permits (Loo et al., 2002). Patients
with CSC should be referred to an endocrinologist if they present with
symptoms indicative of Cushing's syndrome, including facial rounding,
truncal obesity, and the presence of a dorsal fat pad (van Haalen et al.,
T.J. van Rijssen, et al. Progress in Retinal and Eye Research 73 (2019) 100770
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2018b). In this respect, it is important to be aware that the signs and
symptoms associated with Cushing's disease can be very subtle, and CSC
can even be a presenting feature of this disease (van Dijk et al., 2016).
Whether the patient is ‒ or might be ‒ pregnant should be discussed
with women of childbearing age who present with CSC. The possibility
of eradication of Helicobacter pylori infection is described in paragraph
2.3.7.6. Reduction of emotional stress, treating anxiety, a healthy diet,
and enough sleep may be advised, although there is no strong evidence
of positive effects with regard to CSC in this respect.
2.3. Treatment options
2.3.1. Laser photocoagulation
Traditionally, the treatment of choice for CSC has been focal con-
tinuous-wave thermal laser treatment (Leaver and Williams, 1979),
typically with an argon or diode laser, but also with a krypton or xenon
laser (Nicholson et al., 2013; Novak et al., 1987); with the diode laser
being superior to argon laser in terms of BCVA outcome (Verma et al.,
2004). This method of laser treatment targets the focal leakage point(s)
measured on FA and attempts to close the focal defect in the outer
blood-retina barrier by applying photocoagulation to the affected area
of the RPE. Laser photocoagulation should be limited to extrafoveal
leakage sites, as vision loss, scotoma, reduced contrast sensitivity, and/
or CNV can occur at the treated area (Daruich et al., 2015; Gemenetzi
et al., 2010). Although thermal laser treatment can reduce the duration
of SRF, the final BCVA does not differ significantly compared to no
treatment (Robertson, 1986; Robertson and Ilstrup, 1983). Laser coa-
gulation treatment has been shown to reduce the prevalence of SRF
recurrence to 0 out of 29 treated eyes (compared to 7 out of 16 un-
treated eyes); moreover, treatment reduced the time until complete
resolution to an average of 1 month (compared to 19 months for un-
treated eyes) (Burumcek et al., 1997). It should be noted that the 1997
study by Burumcek et al. was conducted before OCT became available.
Recently, navigated laser photocoagulation was suggested as a safe and
effective laser modality for treating CSC (Chhablani et al., 2014; Muller
et al., 2018). Navigated laser photocoagulation integrates the in-
formation obtained using fundus photography and FA in order to
identify the area to be treated; photocoagulation with a 532-nm laser is
then performed automatically by computer at the marked area (Kozak
et al., 2011). Although navigated laser photocoagulation of the focal
leakage point on FA achieves complete resolution of SRF in 75–94% of
patients with cCSC, functional outcome with respect to BCVA is in-
consistent (Chhablani et al., 2014; Muller et al., 2018). A long-term
prospective randomised trial comparing conventional argon laser pho-
tocoagulation with no treatment found no difference between the two
groups with respect to recurrence rate, visual acuity, or Farnsworth-
Munsell 100-hue test outcome (Ficker et al., 1988). Adverse events
reported with laser photocoagulation include CNV at the treatment site
(in 2 out of 25 patients) (Chhablani et al., 2016; Ficker et al., 1988).
Finally, using photocoagulation to treat CSC does not change subfoveal
choroidal thickness (Maruko et al., 2010). At this point it is difficult to
decide if treatment with photocoagulation is warranted in CSC.
2.3.2. Transpupillary thermotherapy
In the field of ophthalmology, transpupillary thermotherapy (TTT)
was first described for treating choroidal melanoma (Oosterhuis et al.,
1995). The goal of TTT is to induce a mild increase in temperature
specifically in the area to be treated (for example, to 45–60 °C after
1min of treatment for choroidal melanoma) (Journee-de Korver et al.,
1992). This increase in temperature may activate a cascade of reactions
that presumably involve the production of heat shock proteins that help
to repair the damaged RPE cells and may also lead to choroidal vascular
thrombosis (Desmettre et al., 2001). Several techniques have been de-
veloped for inducing ocular hyperthermia, including the use of micro-
wave radiation (Lagendijk, 1982), localised current fields (Liggett et al.,
1990), ultrasound (Coleman et al., 1986), and thermoseeds (Mieler
et al., 1989). The precise mechanism by which TTT is effective in
treating CSC is unclear, but it may involve the induction of apoptosis in
endothelial cells and/or vascular thrombosis, which may be useful for
treating the underlying choroidal abnormalities in this disease (Wei and
Yang, 2005). In CSC, TTT can be performed using an 810-nm pulse
diode laser and for this disease it requires a shorter treatment duration
(30–45 s) compared to the treatment of choroidal melanomas, as CSC
does not involve active proliferation of the choroid (Hussain et al.,
2006).
In a study by Hussain et al., 79% of patients with cCSC had a
complete resolution of SRF three months after treatment, and 53% of
treated eyes had an improvement of ≥3 lines of visual acuity (Hussain
et al., 2006). In a case-control study involving 25 patients who received
TTT and 15 observed patients, all of whom had a subfoveal leak, 96% of
the treated patients had complete resolution of SRF within 3 months
compared to only 53% of control-treated patients (Shukla et al., 2008).
However, one eye in the treated group developed subfoveal CNV
(Shukla et al., 2008). Manayath and colleagues performed ‘graded’
subthreshold TTT in 10 eyes with cCSC, initially using 60% of the
threshold power; if the SRF persisted at 1 month, the power was in-
creased to 80% of threshold for a second treatment session (Manayath
et al., 2012). Using this protocol, the authors found that 8 of the 10
treated eyes (80%) had complete resolution of SRF on OCT and 5 (50%)
of eyes had an improvement of BCVA by≥3 lines. In a prospective
study involving 25 patients with cCSC, Mathur and colleagues found
that 52% of patients had complete resolution of SRF at 3 months after
TTT (Mathur et al., 2009). In another study involving 5 patients who
were treated with ICGA-guided TTT, complete resolution of SRF oc-
curred in 2 patients (40%) at the 12-month follow-up visit (Giudice
et al., 2011). In addition, Kawamura and colleagues studied 8 patients
who had severe CSC together with bullous retinal detachment, several
diffuse leakage spots, or fibrin formation and found complete resolution
of SRF in 5 patients within 1 month of receiving TTT treatment
(Kawamura et al., 2012). Manayath and colleagues studied 22 patients
with cCSC who declined to undergo PDT and therefore underwent TTT
(Manayath et al., 2017). The authors found a significant reduction in
mean foveal thickness, but no significant difference in BCVA between
patients who underwent TTT and patients who underwent PDT; inter-
estingly, however, the patients who underwent TTT required more
treatment sessions and had a longer interval until complete resolution
of SRF compared to patients who underwent PDT. Finally, Russo and
colleagues performed a prospective, randomised interventional pilot
study involving 20 patients with cCSC who received TTT with a 689-nm
laser at an intensity of 805mW/m2 for 118 s; all 20 patients had
complete resolution of SRF when assessed 10 months after treatment
(Russo et al., 2017). On rare occasions, side effects such as macular
infarction may occur following TTT (Benner et al., 2002). Therefore,
additional prospective randomised controlled trials are warranted in
order to evaluate further the efficacy and safely of using TTT to treat
CSC.
2.3.3. Subthreshold micropulse laser
The use of a micropulse diode laser can induce more subtle effects in
the outer retina compared to laser photocoagulation. Importantly, at
the appropriate dose micropulse laser treatment can selectively target
the RPE while preserving the photoreceptors and without causing
visible tissue damage. Micropulse laser was first suggested as a viable
option for treating macular oedema after retinal venous occlusion
(Friberg and Karatza, 1997; Moorman and Hamilton, 1999), and in
patients with diabetic retinopathy (Friberg and Karatza, 1997;
Moorman and Hamilton, 1999). The first papers describing the use of
subthreshold micropulse laser for CSC were published a decade later
(Chen et al., 2008; Lanzetta et al., 2008). However, the mechanism of
action underlying micropulse laser treatment is poorly understood, and
large prospective, randomised controlled trials regarding micropulse
laser treatment have not been performed, with the exception of the
T.J. van Rijssen, et al. Progress in Retinal and Eye Research 73 (2019) 100770
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PLACE trial, which compared subthreshold micropulse laser treatment
to half-dose PDT in patients with cCSC (van Dijk et al., 2018b). With
subthreshold micropulse laser, photonic radiation is delivered to the
retina in pulses lasting 0.1–0.5 s, each consisting of a ‘train’ of brief
(100–300 μs) laser pulses. This approach allows for the dissipation of
heat between pulses and minimises collateral damage; thus, the tem-
perature stays below the threshold for denaturing cellular proteins, and
no laser burns are induced. Therefore, the subthreshold laser technique
does not have any visible effects on the retina. With high-density sub-
threshold micropulse laser (HSML) treatment for CSC, the laser spots
are targeted to the hyperfluorescent abnormalities on ICGA (and in
some cases, FA) in a densely packed pattern, with adjacent non-over-
lapping spots focused on the designated treatment area (Luttrull, 2016;
Malik et al., 2015; van Dijk et al., 2018b) (Fig. 5). The radiation is
absorbed by chromophores in the RPE ‒ primarily melanin ‒ and is
dissipated as heat (Sivaprasad et al., 2010). When applied in a sub-
lethal dose, the treatment is believed to increase the expression of heat
shock proteins, which may restore cellular function in the RPE (Sramek
et al., 2011). Although no histopathological differences have been ob-
served between micropulse laser application using 810 nm light com-
pared to 532 nm light when measured in rabbits (Yu et al., 2013), the
treatment's effects appear to differ between RPE cells of various sizes,
shape, and pigmentation types (Pollack et al., 1998).
Several micropulse laser types and strategies have been investigated
in interventional studies involving CSC, as summarised in Table 2. The
wavelengths that have been used in micropulse laser treatment for CSC
include 810 nm, 577 nm, 532 nm, and 527 nm (Ambiya et al., 2016;
Arsan et al., 2018; Behnia et al., 2013; Chen et al., 2008; Kang et al.,
2016; Yadav et al., 2015), and other adjustable laser settings include
the duty cycle, power, spot size, and pulse duration. The duty cycle is
defined as the ratio between the ‘ON’ time and the total (‘ON’ plus
‘OFF’) treatment time and ranges from 5% to 15% in various studies
involving CSC patients (Breukink et al., 2016b; Maruko et al., 2017).
The power setting of the micropulse laser determines the intensity of
the laser and ranges from 90mW to 1800mW in published studies
(Wood et al., 2017). The spot size refers to the size of each individual
micropulse laser treatment spot and ranges between 100 μm and
200 μm (Ntomoka et al., 2018; Roca et al., 2018). Pulse duration (or
pulse envelope) is the time interval between each new pulse cycle and
ranges from 100ms to 300ms (Ambiya et al., 2016; Malik et al., 2015).
Thus, to achieve a duty cycle of 5–15% with a pulse duration of 200ms
divided into 100 micropulses, the ‘ON’ time of the micropulse laser per
2ms micropulse will be 0.1–0.3 ms (Abd Elhamid, 2015). Theoretically,
the energy can be delivered to the retina with more precision using a
smaller spot size. The combination of various settings determines the
‘dose’ delivered to the retina, and this dose should be high enough to
achieve a therapeutic effect, but should not be so high that RPE or
neuroretinal damage is induced. To date, no large prospective rando-
mised controlled trials have been performed to compare various mi-
cropulse laser protocols. To complicate the analysis further, many set-
tings vary between protocols, including the laser wavelength, making it
difficult to compare the results of different treatment studies and de-
termine the feasibility of using HSML for CSC.
Several outcomes have been evaluated following HSML treatment,
including retinal thickness (Koss et al., 2012; Kretz et al., 2015; Park
et al., 2017), choroidal thickness (Arsan et al., 2018), resolution of SRF
(Chen et al., 2008), decrease in SRF height on OCT (Arsan et al., 2018),
retinal sensitivity on microperimetry (Abd Elhamid, 2015), BCVA
(Ambiya et al., 2016; Kim et al., 2015c; Roisman et al., 2013), and
adverse events (Roca et al., 2018). Overall, 36–100% of patients with
cCSC had complete resolution of SRF after HSML treatment based on
retrospective studies and case series (Table 2) (Chen et al., 2008; Scholz
et al., 2016, 2017). Scholz et al. used ICGA-guided 577 nm HSML
treatment in 42 eyes and found that a second treatment was required in
41% of cases at the 6-week follow-up visit (Scholz et al., 2016). Al-
though the authors did not report the percentage of patients who
achieved complete resolution of SRF after this second HSML treatment,
74% of patients had a decrease in central retinal thickness of ≥20 μm
after the second treatment (Scholz et al., 2016). The mean follow-up
time of 26 eyes with cCSC in a study by Chen and colleagues was 9.5
months, and the authors performed up to three FA-guided subthreshold
micropulse laser treatments using an 810 nm laser; they found that 13
out of 26 patients (50%) achieved complete resolution of SRF after
these micropulse laser treatments (Chen et al., 2008). In the PLACE
trial, the only large prospective, multicentre randomised controlled
treatment trial studying HSML in cCSC conducted to date, complete
resolution of SRF was achieved in only 14% and 29% of cases at 2 and
7–8 months, respectively, in the HSML group (van Dijk et al., 2018b).
The rates of SRF resolution in the PLACE trial are lower than those
reported previously by retrospective studies and smaller prospective
studies regarding HSML in cCSC. This difference in outcome may be due
to the retrospective nature and relatively small sample sizes of the
previous studies, as well as possible differences in inclusion and/or
exclusion criteria.
Micropulse laser treatment may be more effective in cCSC eyes with
focal leakage compared to eyes with diffuse leakage (Chen et al., 2008).
According to data from a PLACE trial subgroup consisting of 79 HSML-
treated patients with cCSC with either focal or diffuse leakage on FA,
41% and 21% of patients with focal or diffuse leakage, respectively, had
complete resolution of SRF at 7–8 months (van Rijssen et al., 2019).
These findings suggests that HSML may be more effective in cCSC with
focal leakage on FA. Nevertheless, a significantly higher percentage of
patients with cCSC who were treated with half-dose PDT had complete
resolution of SRF compared to the HSML-treated group, with rates of
75% versus 41%, respectively, among patients with focal leakage and
57% versus 21%, respectively, among patients with diffuse leakage
(van Rijssen et al., 2019).
Fig. 5. Multimodal imaging of a 48-year-old man with chronic central serous
chorioretinopathy, who was treated with high-density subthreshold micropulse
laser (HSML). Optical coherence tomography shows subretinal fluid that in-
cludes the fovea (A). A clear area of focal leakage can be seen on fluorescein
angiography (B). Mid-phase (10min after injection) indocyanine green angio-
graphy (ICGA) shows hyperfluorescent areas (C). The area that was treated with
HSML is depicted in D. A schematic illustration of the pattern of closely spaced
laser spots (shown larger than the actual spot size that was used for HSML
treatment) is depicted within the area delineated by the red line. The complete
area of hyperfluorescence on indocyanine green angiography within the vas-
cular arcades was treated with HSML laser. The subretinal fluid decreased but
persisted after this treatment (E). (For interpretation of the references to colour
in this figure legend, the reader is referred to the Web version of this article.)
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It has been suggested that performing HSML treatment directly after
intravenous administration of indocyanine green may increase the se-
lectivity for RPE cells (Ricci et al., 2004, 2009). During this procedure,
patients receive an intravenous injection of 25mg indocyanine green
dissolved in 2mL of a 5% glucose solution. After a brief waiting period
of 15–20min, patients undergo HSML treatment with an 810 nm laser.
In a small prospective case series, 5 out of 7 patients with cCSC had
complete resolution of SRF, and the amount of SRF was reduced in the
other two patients within 8 weeks following treatment (Ricci et al.,
2009). In summary, the efficacy of subthreshold micropulse laser
treatment for cCSC can be improved by standardising the laser settings
and understanding the mechanism of action, and additional prospective
randomised clinical trials will help determine its feasibility as a treat-
ment modality for CSC (Wood et al., 2017).
2.3.4. Photodynamic therapy (PDT)
Although PDT was originally developed as a treatment for skin
cancer, subsequent improvements in lasers and powerful light sources
eventually paved the way for its introduction in the field of ophthal-
mology (Daniell and Hill, 1991; Miller and Miller, 1993; Miller et al.,
1991, 1995; Yannuzzi et al., 2003). In PDT applications in ophthal-
mology, the benzoporphyrin derivate verteporfin is currently approved
for use in treating retinal disease, as it has a high affinity for the RPE
(Kramer et al., 1996; Ziemssen and Heimann, 2012). The high lyso-
somal activity in the RPE can lead to the binding of verteporfin to
plasma low density lipoproteins, which bind to surface receptors of the
cell membrane of vascular and reticuloendothelial cells (Schmidt-
Erfurth and Hasan, 2000). However, compared to photocoagulation,
the PDT-induced effects to the RPE are far less destructive (Schmidt-
Erfurth and Hasan, 2000). The treatment effect of PDT in CSC is pre-
sumably based on the formation of free radicals upon illumination of
the treatment site ‒ specifically, the choriocapillaris ‒ which leads to
damage to the vascular endothelium and hypoperfusion, and sub-
sequent remodelling of the vessels in the capillary bed underlying the
damaged RPE. Because of the treatment's high selectivity, retinal pho-
toreceptors are spared (Chan et al., 2003; Schlotzer-Schrehardt et al.,
2002). In ophthalmology, PDT was originally developed for treating
CNV secondary to AMD (Newman, 2016). After it was approved for use
in treating AMD, verteporfin was soon used off-label in PDT for treating
CSC, particularly cCSC. The studies that were performed to evaluate
PDT in 50 or more patients with CSC are summarised in Table 3.
Yannuzzi and colleagues were among the first groups to report PDT as a
possible treatment strategy for cCSC (Yannuzzi et al., 2003). In the
initial reports, verteporfin was used at the same dose as for neovascular
AMD (‘full-dose PDT’, 6 mg/m2). Later, however, several reduced-in-
tensity PDT regimens such as half-dose, half-fluence, and half-time PDT
(see section 2.3.4.1) were developed in order to avoid a possible com-
plication of profound angiographic closure that has been reported ‒
albeit rarely ‒ following PDT for neovascular AMD (see section 2.3.4.4.)
(Alkin et al., 2014; Neves et al., 2016; Shin et al., 2011; Shiode et al.,
2015).
Choroidal thickness can transiently increase immediately following
PDT treatment for CSC. In one study, mean choroidal thickness in-
creased to 119% of pre-treatment thickness in 8 eyes at 2 days after
treatment (Maruko et al., 2010). This transient effect on choroidal
thickness can be accompanied by a transient increase in the height of
the serous neuroretinal detachment, and increased visual symptoms
have been reported in up to 38% of treated patients measured up to 4
weeks after treatment (Maruko et al., 2010; van Dijk et al., 2018a).
Changes in choroidal thickness and SRF height typically decrease
within 1 week of treatment and stabilise at 1 month, and are often
accompanied by a resolution of SRF, gradually improving visual acuity,
and reduced visual symptoms compared to pre-treatment levels
(Maruko et al., 2011; van Dijk et al., 2018b). After PDT treatment for
unilateral CSC, choroidal thickness in the treated eye can decrease to
the same choroidal thickness value as in the unaffected eye, resulting inTa
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no significant difference in choroidal thickness between the two eyes
(Pryds and Larsen, 2012). This finding suggests that PDT reduces the
choroidal vascular hyperpermeability and thickening that play a key
role in the pathogenesis of CSC (Izumi et al., 2017; Maruko et al.,
2010).
2.3.4.1. Treatment algorithms and mode of action. The efficacy of using
PDT with verteporfin relies upon the proper selection of the target area
to be irradiated with a circular spot of light. A common selection
strategy is to set the centre and diameter of this spot so that it covers the
area of hyperfluorescent abnormalities on mid-phase ICGA and the
corresponding point(s) of leakage on FA and OCT, as this is the
apparent point of origin for the SRF (van Dijk et al., 2018b; Yannuzzi
et al., 2003) (Fig. 6). In preparation for the procedure, the pupil of the
eye to be treated is first dilated using a mydriatic agent. Subsequently,
either 6mg/m2 (for full-dose PDT) or 3mg/m2 (for half-dose PDT)
verteporfin (Visudyne®; Novartis, Basel, Switzerland or Bausch & Lomb,
Rochester, NY, USA) is delivered via an intravenous infusion over a 10-
min time course. Within 10–15min after the start of the verteporfin
infusion, an anaesthetic eye drop (e.g. oxybuprocaine 0.4%) is
administered to the eye to be treated, and a contact lens ‒ typically,
a 1.6x magnification PDT lens ‒ is positioned on the cornea. Light at
689 nm is then applied to the area to be treated at a fluence of 50 J/cm2
for 83 s. Alternatively, half-fluence (25 J/cm2) PDT can be used, with a
full dose of verteporfin (6mg/m2) and full treatment duration (83 s). A
final option is half-time PDT, which uses full-dose verteporfin (6mg/
m2), full fluence (50 J/cm2), and a treatment duration of 42 s. Patients
should be advised to avoid exposure to direct sunlight and other sources
of UV radiation for 48 h after receiving half-dose PDT, and this period
of time should be increased or decreased accordingly based on the
verteporfin dose.
Half-dose PDT has been reported to be as effective as ‒ or superior
to ‒ full-dose, half-fluence, and half-time PDT regimens with respect to
both aCSC and cCSC. Because of the reduced risk of systemic side effects
(see paragraph 2.6.4.), half-dose PDT is preferred in some treatment
centres. Most studies of PDT for CSC involved patients with cCSC, in
which the spontaneous resolution of SRF is less common than in aCSC
(see section 1.1.1.). Alkin and colleagues found no significant difference
in efficacy between half-dose PDT and half-fluence PDT in treating
cCSC (Alkin et al., 2014). In contrast, Nicolo and colleagues reported
that half-dose PDT group led to complete resolution more rapidly than
half-fluence PDT, with 86% and 61% of patients with cCSC, respec-
tively, reaching complete resolution of SRF at the 1 month follow-up
point (Nicolo et al., 2014). In other studies, half-fluence PDT was found
to be just as effective as full-fluence PDT in treating cCSC (Shin et al.,
2011), and half-dose PDT was found to be just as effective as full-dose
PDT in treating persistent CSC (Boni et al., 2012). Moreover, efficacy is
similar between half-time PDT and half-dose PDT (Liu et al., 2016;
Shiode et al., 2015). In a retrospective case series, Liu and colleagues
compared half-dose PDT with full-fluence to half-dose PDT with half-
fluence in patients with cCSC and found that complete resolution of SRF
was achieved in 93% and 64% of cases, respectively, which was a
statistically significant difference (Liu et al., 2014). In a study designed
to determine the optimal verteporfin dose for PDT in treating aCSC,
Zhao and colleagues tested a range of doses from 10% to 70% and
found that 30% was the lowest effective dose (Zhao et al., 2009).
Moreover, in their subsequent study, the same group found that half-
dose PDT (i.e. with a 50% verteporfin dose) was superior to a 30% dose,
with 95% of patients achieving complete SRF resolution, compared to
only 75% of patients in the lower dose group (Zhao et al., 2015). In a
different retrospective study involving 16 patients with cCSC, half-dose
(3mg/m2) PDT was found to be superior to one-third dose (2mg/m2)
PDT, with 100% cases achieving complete resolution of the serous
neuroretinal detachment compared to only 33% in the one-third dose
group (Uetani et al., 2012). Thus, PDT treatment using a one-third dose
of verteporfin appears to be suboptimal with respect to achieving
complete resolution of SRF in CSC (Dang et al., 2014).
2.3.4.2. PDT in acute CSC. In patients with aCSC, PDT treatment can
provide faster SRF resolution, more rapid recovery of retinal sensitivity
(Casalino et al., 2016; Hagen et al., 2013), and higher BCVA compared
to placebo (Chan et al., 2008a). Indeed, complete resolution of SRF has
been reported in 74–100% of patients following PDT treatment (Chan
et al., 2008a; Kim et al., 2014; Zhao et al., 2015). Chan and colleagues
performed a randomised controlled trial to compare half-dose ICGA-
guided PDT with placebo in patients with aCSC and found a
significantly larger improvement in BCVA in the PDT-treated group;
moreover, 95% of patients achieved complete resolution of SRF
following PDT, which was significantly higher than the placebo
group, in which only 58% of patients achieved complete resolution
(Chan et al., 2008a). These results suggest that half-dose PDT may be a
suitable treatment option for aCSC, despite the high probability of
spontaneous resolution of SRF if left untreated. In a non-randomised
retrospective study comparing 11 patients who received half-dose FA-
guided PDT and 10 patients who received placebo treatment, Kim and
colleagues found complete resolution of SRF in 80% of aCSC patients at
1 month after PDT, 100% at 3 months after PDT, and 90% at 12 months
after PDT, compared to only 18%, 27%, and 64% of patients,
respectively, in the placebo group (Kim et al., 2014). Both ICGA-
guided and FA-guided PDT treatment can be effective in aCSC.
Achieving rapid resolution of SRF can be important in order to
quickly improve BCVA in some patients, for example patients who
depend heavily on optimal BCVA for professional reasons (Lu et al.,
Fig. 6. Multimodal imaging of a 37-year-old man diagnosed with chronic
central serous chorioretinopathy, who was treated with half-dose photo-
dynamic therapy (PDT). Multifocal serous neuroretinal detachments are present
in the macula, including the fovea (A). Diffuse hyperfluorescent retinal pigment
epithelial abnormalities can be seen nasally of the optic disc on 3-min fluor-
escein angiography, with relatively limited abnormalities and discrete leakage
in the macula (B). In contrast, indocyanine green angiography (10min after
injection of indocyanine green) shows intense, multifocal hyperfluorescence
that is much more extensive than the abnormalities on fluorescein angiography
(C). The area that was treated with half-dose PDT included most of the area of
hyperfluorescence that fitted in a single PDT laser spot (area within the red
circle, D). After a single PDT treatment, a complete resolution of subretinal fluid
was observed on optical coherence tomofraphy (OCT) (E), with a decrease in
choroidal thickness as compared to the OCT image before treatment (A).
Toward the optic disc there is increasing photoreceptor layer atrophy without
pigment epithelium loss, a characteristic finding in central serous chorior-
etinopathy. (For interpretation of the references to colour in this figure legend,
the reader is referred to the Web version of this article.)
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2016; Ober et al., 2005; Tsai and Hsieh, 2014). However, Kim et al.
found that long-term BCVA outcome and the prevalence of complete
resolution of SRF did not differ significantly between patients who
received half-dose PDT compared to patients who received placebo,
with 90% and 64% of patients achieving complete resolution in the PDT
and placebo groups, respectively, after 12 months of follow-up (Kim
et al., 2014). Importantly, treatment with low-fluence PDT may also
decrease the risk of recurrence of SRF in patients with aCSC patients, as
a recent study by Ozkaya and colleagues found that 51% of untreated
patients had recurrence compared to only 25% of patients who were
treated with low-fluence PDT (Ozkaya et al., 2016). Finally, our group
performed a retrospective study of 295 eyes with aCSC and found that
SRF recurred in 24% of untreated eyes compared with only 4% of the
eyes that received early treatment consisting primarily of FA-guided
half-dose PDT (Mohabati et al., 2019).
Some patients have an isolated PED without the presence of SRF.
When these patients have such an isolated PED in combination with
pachychoroid changes, these cases can be considered a variant of pa-
chychoroid pigment epitheliopathy (Warrow et al., 2013). Given that
PED is a frequent and possibly essential element of the pathogenesis of
CSC, it is not surprising that non-neovascular PED without serous de-
tachment of the retina has been seen in fellow eyes of patients with CSC
and in patients without CSC, some of whom eventually convert to CSC
(Arif et al., 2018). In cases where an isolated PED is found under the
fovea, associated metamorphopsia may give rise to considerable bino-
cular visual complaints. This has prompted attempts to flatten the PED
by (half-dose) PDT in long-standing cases of isolated PED with persis-
tent visual symptoms. Arif et al. found that a single session of PDT was
followed by complete resolution of the PED in 7 (78%) of 9 eyes. Of 13
untreated eyes, 5 eyes (38%) underwent spontaneous resolution of the
PED. PDT may be useful especially in cases with underlying pachy-
choroid on OCT and hyperfluorescent choroidal congestion and hy-
perpermeability on ICGA.
2.3.4.3. PDT in chronic CSC. In 2003, the use of ICGA-guided full-
setting PDT was first applied to patients with cCSC, with Yannuzzi and
colleagues reporting complete resolution of SRF in 12 out of 20 eyes
(60%) within 6 weeks (Yannuzzi et al., 2003). In the same year, Cardillo
Piccolino and colleagues reported complete resolution in 12 out of 16
eyes (75%) within 1 month (Cardillo Piccolino et al., 2003). Although
the risk of both short-term and long-term side effects appears to be
relatively low in standard full-setting PDT (see section 2.3.4.4.)
(Vasconselos et al., 2013), several studies have experimented with
using either a reduced verteporfin dose for treating cCSC (Chan et al.,
2008b; Nicholson et al., 2013), half-fluence PDT (Nicolo et al., 2014;
Smretschnig et al., 2013), or half-time PDT (Liu et al., 2016; Shiode
et al., 2015). In the PLACE trial, Van Dijk et al. found complete
resolution of SRF after ICGA-guided half-dose PDT in 51% and 67% of
patients after 6–8 weeks and 7–8 months, respectively (van Dijk et al.,
2018b). In addition, a non-randomised prospective case series of 18
patients revealed that 85% of patients achieved complete resolution of
SRF at 1 month after treatment (Lai et al., 2006). The long-term efficacy
of half-dose PDT is generally favourable, with SRF resolution rates of
91% and 81% at a mean follow-up of 19 and 50 months, respectively
(Dhirani et al., 2017; Haga et al., 2017). In a retrospective study in 204
Asian cCSC patients, Fujita and colleagues reported complete resolution
of SRF in 89% of patients at 12 months after treatment (Fujita et al.,
2015). Finally, a retrospective study in 52 predominantly Asian cCSC
patients found that 93% of patients with cCSC had complete SRF
resolution 34 months after reduced-setting PDT (Kim et al., 2015d),
while a separate retrospective study found that 97% of Asian patients
with cCSC had no detectable SRF 36 months after half-dose PDT (Lai
et al., 2016).
Another important measure of successful treatment for CSC ‒ in
addition to complete resolution of SRF ‒ is retinal sensitivity on mi-
croperimetry. Although BCVA is an important parameter in macular
diseases such as CSC, BCVA can still be relatively preserved in patients
with CSC despite the presence of SRF (Karakus et al., 2013). In the
PLACE trial, the mean retinal sensitivity of patients with cCSC im-
proved by 2 dB and 3 dB at 6–8 weeks and 7–8 months, respectively,
after half-dose PDT (van Dijk et al., 2018b). Mean retinal sensitivity
was also reported to improve within 1 month following half-dose PDT
in patients with cCSC, whereas an improvement in BCVA was detected
after 3 months (Fujita et al., 2012b). This improved retinal sensitivity
may be correlated with reattachment of the cone outer segment tips and
the ellipsoid line on OCT (Fujita et al., 2012a). Despite an increase in
retinal sensitivity following PDT for unilateral CSC, the final retinal
sensitivity remains generally lower than in the unaffected eye (Fujita
et al., 2012b; Sanguansak et al., 2015; Senturk et al., 2011).
Reduced-setting PDT for cCSC has a favourable long-term BCVA
outcome, with an average gain of 5 ETDRS letters measured 7–8 months
after treatment (van Dijk et al., 2018b), and a mean increase in BCVA
from 0.11 to −0.01 logarithm of the minimal angle of resolution
(LogMAR) units at 12 months (Fujita et al., 2015). In a 4-year follow-up
study, Silva and colleagues reported that patients who received full-
setting PDT had a mean increase in BCVA from 59 ETDRS letters at
baseline to 67 ETDRS letters at final follow-up visit (Silva et al., 2013).
Some patients with cCSC may experience a temporary decrease in BCVA
shortly after PDT, which may be due to an abrupt reattachment of
photoreceptors and/or a temporary increase in SRF, which occasionally
occurs together with transient thickening of the choroid (Iacono et al.,
2018; van Dijk et al., 2018a). Treating cCSC using PDT can also lead to
a decrease in central retinal thickness, which has been described as a
desired effect (Ohkuma et al., 2013). However, large variations in the
methods used to measure central retinal thickness preclude a compre-
hensive analysis of cumulative data (van Rijssen et al., 2018a). In a
study in which SRF was included in the measure of central retinal
thickness, the decrease in thickness was not correlated with BCVA
(Copete et al., 2012). However, SRF should not be included when
measuring central retinal thickness. Thus, to exclude SRF, which was
inappropriately included in some of the previous studies regarding PDT
in CSC, the distance between the internal limiting membrane and the
ellipsoid zone on spectral-domain OCT can be measured and used as a
surrogate measure of central retinal thickness (van Rijssen et al.,
2018a). Using this approach, we recently reported that half-dose PDT
actually causes a slight increase in central retinal thickness.
Patients who do not achieve complete SRF resolution after reduced-
setting PDT may experience a smaller reduction in central retinal
thickness compared to patients who achieved complete resolution (Kim
et al., 2015d). Recurrent SRF after initial complete SRF resolution fol-
lowing ICGA-guided half-dose PDT for cCSC occurred in 13% of pa-
tients measured at a mean follow-up of 19 months (Dhirani et al.,
2017), and in 18% of patients measured at a mean follow-up of 50
months (Haga et al., 2017). In a retrospective study of 75 eyes with CSC
treated with half-dose PDT or placebo and followed for at least 3 years,
only 20% of eyes in the half-dose PDT group had recurrent CSC com-
pared to 53% of untreated eyes (Lai et al., 2015). Interestingly, the rate
of recurrence after half-dose PDT is higher among patients with bi-
lateral cCSC compared to patients with unilateral cCSC (Lai et al.,
2016). Moreover, a 4-year follow-up study of cCSC patients by Silva and
colleagues found that 3 out of 46 eyes (6.5%) had persistent SRF 4 years
after full-dose PDT (Silva et al., 2013).
Several putative predictors of treatment outcome following PDT for
CSC have been proposed. For example, PDT can be ineffective and/or
have a high rate of recurrence in patients with cCSC who have: 1)
PCRD, 2) an absence of an intense hyperfluorescent area on ICGA, 3)
poor baseline BCVA, 4) a disruption in the ellipsoid zone, 5) a diffuse
hyperfluorescent pattern on ICGA, and/or 6) the presence of shallow
irregular RPE detachments on OCT (Cardillo Piccolino et al., 2008a;
Chung et al., 2018; Fujita et al., 2015; Inoue et al., 2010; Nicolo et al.,
2012; van Rijssen et al., 2018b). On the other hand, patients with cCSC
generally respond better to half-dose PDT compared to HSML treatment
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regardless of the presence of either focal or diffuse leakage on FA (van
Rijssen et al., 2019). This may indicate that the same pathophysiolo-
gical processes are involved in both cCSC with focal leakage and cCSC
with diffuse leakage. When subretinal deposits are visible on FAF, fo-
veal damage may already exist and may not be restored following PDT
(Pryds and Larsen, 2013). When atypical features such as massive
exudation with large serous retinal detachment and multiple white
subretinal deposits are present, PDT can also be effective. An absence of
hyperfluorescent abnormalities on ICGA in cCSC can be predictive of a
non-resolving serous neuroretinal detachment following PDT (Inoue
et al., 2010; van Rijssen et al., 2018b). Finally, Breukink and colleagues
found no difference between cCSC patients who use corticosteroids and
cCSC patients who do not use corticosteroids with respect to outcome
following PDT, with complete resolution of SRF in 69% and 50% of
patients, respectively (Breukink et al., 2016a).
2.3.4.4. Safety of PDT in CSC. To date, only a few side effects have been
reported in association with PDT using the standard (i.e. ‘full’)
treatment settings that were previously described for treating AMD.
These side effects can include nausea, headache, dyspnoea, syncope,
dizziness, a decrease in BCVA, and possible side effects at the site of
verteporfin infusion (according to the package insert for verteporfin),
including pain, oedema, inflammation, and extravasation. Rare side
effects that have been reported include hypersensitivity reactions to the
infusion (including anaphylactic reactions with convulsions),
temporary renal artery stenosis, and non-perfusion of the choroidal
vasculature at the treated area. Therefore, patients should be monitored
closely during the PDT procedure. Contraindications for PDT include
pregnancy, porphyria, and poor liver function.
Neither systemic nor ocular side effects were observed in a study
involving 46 eyes with cCSC in 42 patients who were followed for 4
years after full-dose PDT treatment (Silva et al., 2013). In contrast,
adverse events were reported in non-human primates after full-dose
PDT and included RPE proliferation, closure of the choroidal vascu-
lature, foveal thinning, and retinal oedema (Tzekov et al., 2006). The
severity and risk of adverse effects following PDT can increase when
fluency is doubled from the standard fluence of 50 J/cm2, and corre-
sponding to 4 times the fluence used in half-fluence PDT (25 J/cm2)
that is often used for the treatment of CSC (Schlotzer-Schrehardt et al.,
2002). In a meta-analysis of studies comparing full-dose PDT and pla-
cebo-treated patients with AMD and CNV, Azab and colleagues found a
higher rate of visual disturbances in the PDT-treated group (22–42%)
compared to the placebo group (16–23%), including abnormal vision,
decreased vision, and visual field defects (Azab et al., 2004). Moreover,
they found that 1–5% of patients treated with full-dose PDT had an
acute decrease in visual acuity (Azab et al., 2004); interestingly, BCVA
still improved by at least 1 line in 71% of patients who experienced this
acute decrease in visual acuity (Arnold et al., 2004). Few severe side
effects have been reported in association with PDT for CSC. For ex-
ample, a case report of one patient with cCSC and two patients with
serous PED who developed severe choroidal ischaemia after receiving
full-setting PDT has been published (Lee et al., 2009). Moreover, a
transient loss of visual acuity was reported in a patient with cCSC fol-
lowing half-fluence PDT; visual acuity recovered within 22 months
(Gutierrez-Hernandez et al., 2015). When using full-dose PDT in pa-
tients with CSC, the presence of fibrin underneath the neurosensory
detachment may increase the treatment reaction by conjugating ver-
teporfin with fibrin. Therefore, caution is advised in these cases with
subretinal fibrin (Fig. 4A–D), although there currently is no clear evi-
dence with respect to using PDT in such cases.
To minimise the risk of PDT-related side effects, reduced-setting
PDT was developed for CSC. Overall, reduced-setting PDT is well-tol-
erated, and no treatment-related severe adverse events such as CNV or
RPE atrophy have been reported by the many studies conducted to date
(Liu et al., 2014; Tseng and Chen, 2015; van Dijk et al., 2018b). The
relatively low risk of systemic photosensitivity (i.e. sunburn on the
skin) can be reduced further using half-dose PDT instead of half-fluence
PDT. Thus, treating ophthalmologists may wish to consider whether
this side effect is a high risk for their patients and ‒ if so ‒ may opt for
half-dose PDT rather than half-fluence or half-time PDT. In a study
involving 39 aCSC patients who were treated with half-dose PDT, no
ocular or systemic side effects were observed during 12 months of
follow-up (Chan et al., 2008b). Similarly, in the PLACE trial, no ocular
or systemic side effects were observed in 89 cCSC patients treated with
half-dose PDT during a follow-up period of 7–8 months (van Dijk et al.,
2018b). Recently, Fujita and colleagues reported no systemic or ocular
side effects in 204 eyes with cCSC treated with half-dose PDT, with the
sole exception of a polypoidal lesion 8 months after treatment in one
eye; however, given that CSC is part of the pachychoroid disease
spectrum, this side effect cannot be attributed definitively to PDT, but
may represent the natural course of the disease (Fujita et al., 2015).
Despite the overall favourable safety profile of PDT in treating CSC, a
retrospective study involving either full-dose or reduced-setting PDT
revealed RPE atrophy in 10 out of 250 eyes (4%) and an acute severe
visual decrease (not further specified) in 4 out of 265 eyes (1.5%) (Lim
et al., 2014). In a study involving 199 patients with severe cCSC with
pre-existing fovea-involving RPE atrophy, Mohabati and colleagues
found a decrease of> 2 ETDRS lines in 9 patients (5%) after PDT; in
three of these patients (2%), the decrease in BCVA was permanent and
involved a loss of 11–13 ETDRS letters (Mohabati et al., 2018b). Al-
though the vision loss in this very specific category of severe cCSC with
fovea-involving RPE atrophy may be due to the PDT treatment, it is also
possible that the progressive RPE atrophy is part of the natural course of
this more severe form of cCSC. However, this relatively small minority
of patients with cCSC with extensive foveal RPE atrophy should be
counselled regarding the risk of further vision loss following PDT, and
further studies are needed in order to investigate these findings in
further detail.
Some patients with cCSC may require re-treatment with reduced-
setting PDT due to recurrence of SRF or persistent SRF. However, in the
PLACE trial, a second treatment with half-dose PDT was able to achieve
complete resolution of SRF in only 32% of cases (van Dijk et al., 2018b).
The risk of not responding to PDT treatment may be high in patients
who present with hypofluorescence on ICGA at the area corresponding
with the focal leakage point on FA (Inoue et al., 2010; van Rijssen et al.,
2018b). Repeat PDT treatment may still be effective, particularly in
patients who have a serous retinal detachment with SRF when the
leakage results from persistent ‒ or recurrent ‒ hyperfluorescent chor-
oidal changes on ICGA in association with focal leakage on FA. For
example, this may be the case when these areas were not included in
the initial PDT treatment spot. Whether repeat treatment(s) can induce
cumulative changes in the choroid that can eventually lead to adverse
effects such as RPE atrophy is currently unknown; therefore, some
groups limit the maximum number of PDT treatments for CSC to 2 or 3
treatments per eye.
2.3.5. Intravitreal injection of anti-vascular endothelial growth factor
(VEGF)
Experimental evidence suggests that inhibiting VEGF has an anti-
proliferative and anti-hyperpermeability effect on choroidal endothelial
cells (Gragoudas et al., 2004; Peters et al., 2007). In addition, several
clinical studies involving patients with AMD and diabetic macular oe-
dema have shown that inhibiting VEGF has a robust inhibitory effect on
leakage and fibrovascular proliferation, decreases choroidal blood flow,
and reduces central choroidal thickness (Koizumi et al., 2016; Nourinia
et al., 2018; Roohipoor et al., 2016). Because CSC is believed to origi-
nate from the choroidal vasculature, intravitreal injections of anti-VEGF
compounds such as bevacizumab, ranibizumab, and aflibercept have
been suggested as a possible treatment for CSC by modifying choroidal
vascular permeability (Torres-Soriano et al., 2008). However, the use of
anti-VEGF injections for treating CSC is generally off-label, so informed
consent should be obtained from the patient prior to treatment,
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emphasizing this off-label use.
Although some studies have investigated the use of anti-VEGF for
CSC (see Table 4 for a summary of studies published to date), no large,
prospective randomised controlled clinical trials have been performed.
Some studies found a positive effect. For example, Artunay and col-
leagues found that 80% of 15 patients treated with bevacizumab had
complete resolution of SRF, compared to 53% of 15 untreated control
group patients (Artunay et al., 2010). In a prospective study of 20 pa-
tients with aCSC who received ranibizumab and 20 patients who re-
ceived no treatment, SRF resolved in 4 weeks compared to 13 weeks,
respectively (Kim et al., 2013). In a randomised, non-controlled pilot
study involving 8 cCSC eyes treated with 3 intravitreal injections of
ranibizumab, 2 eyes (25%) had complete resolution of SRF at 3 months
(Bae et al., 2011). However, in a subsequent prospective study with
ranibizumab, Bae and colleagues reported complete resolution in only
13% of cCSC eyes treated with ranibizumab after 12 months, compared
to 89% of eyes treated using low-fluence PDT (Bae et al., 2014). Despite
these positive reports, however, a meta-analysis failed to confirm the
putative positive effects of bevacizumab, ranibizumab, or aflibercept
for aCSC, although the authors did suggest that certain subtypes of
cCSC might benefit from anti-VEGF treatment (Chung et al., 2013; Ji
et al., 2017). This may be particularly true for patients with CSC with
associated CNV (Chan et al., 2007; Chhablani et al., 2015).
A prospective pilot study involving 12 cCSC patients revealed that
intravitreal aflibercept led to complete resolution of SRF in 6 patients
(50%), but had no significant effect on BCVA (Pitcher et al., 2015).
Moreover, changes in choroidal thickness have been observed after
intravitreal injections of anti-VEGF. Specifically, Kim and colleagues
reported that choroidal thickness was decreased by an average of 22 μm
in 42 cCSC eyes measured at a mean follow-up of 9 months after the
start of intravitreal injections of bevacizumab (Kim et al., 2015b). This
decrease is similar to the results reported using aflibercept and bev-
acizumab for AMD, which both resulted in a decrease in choroidal
thickness of approximately 36 μm (Koizumi et al., 2016; Ting et al.,
2016). Because these studies were performed before the availability of
OCT angiography, it is unclear whether the SRF that resolved occurred
due to CSC or due to secondary CNV, which is difficult to distinguish
based on FA and ICGA images. Given the lack of large prospective trials
and the unknown explanation for its efficacy in CSC, intravitreal in-
jections of anti-VEGF agents should probably be limited to patients with
CSC together with CNV and/or polypoidal choroidal vasculopathy, as
discussed in section 3.3.
2.3.6. Antagonists of mineralocorticoid receptors (MR) and glucocorticoid
receptors
Elevated levels of cortisol and endogenous mineralocorticoid dys-
function have been described in CSC patients (Haimovici et al., 2003).
Moreover, there appears to be an association between corticosteroid use
and CSC, and rats that received corticosteroids have increased expres-
sion of MRs. These findings led to the hypothesis that MR antagonists
may be used to treat CSC (Daruich et al., 2015; Zhao et al., 2010, 2012).
Pilot studies using the MR antagonists eplerenone and spironolactone in
patients with CSC have yielded promising results (Bousquet et al., 2013,
2015) (see Table 5). However, the patient's renal function and po-
tassium levels should be monitored closely before treatment and at
regular intervals during treatment, as MR antagonists can induce hy-
perkalaemia, which has been associated with cardiac arrhythmia. Pa-
tients whose serum potassium level exceeds 5.5 mEq/L and/or have a
creatinine clearance rate of ≤30mL/min should not receive treatment
with MR antagonists. On the other hand, patients with a relatively thick
choroid (> 515 μm) may respond better to treatment with MR an-
tagonists (Bousquet et al., 2019).
Glucocorticoids likely play a role in the pathogenesis of CSC, and
glucocorticoid receptors are expressed in both the retina and choroid
(Brinks et al., 2018; Zhao et al., 2010). In rats, corticosterone can cause
choroidal thickening, a feature common among patients with CSCTa
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(Zhao et al., 2012). This finding has prompted experimental treatment
of CSC using the glucocorticoid receptor antagonist mifepristone
(Jampol et al., 2002).
2.3.6.1. Spironolactone. Spironolactone is a potassium-sparing diuretic
that binds to the distal tubule in the kidney as a binding competitor of
aldosterone. Spironolactone slows the exchange of sodium and
potassium in the distal tubule and has been approved for treating
congestive heart failure and primary hyperaldosteronism. The most
common side effects of spironolactone (reported in> 10% of treated
patients) are headache, diarrhoea, fatigue, gynaecomastia, decreased
libido, and menstrual disruption (Delyani, 2000). Patients treated with
spironolactone must be monitored closely for hyperkalaemia, which
can induce cardiac arrest. Patients with diabetes mellitus, liver
disorders, kidney disorders, and elderly patients are particularly at
risk. Contraindications for spironolactone use include the concomitant
use of potassium supplements, the use of potassium-sparing diuretics,
the use of potent CYP3A4 inhibitors, or the combined use of an
angiotensin-converting enzyme inhibitor with an angiotensin receptor
blocker, as taking these drugs together with spironolactone can increase
the risk of hyperkalaemia and subsequent cardiac arrhythmia.
Several studies have shown beneficial effects of spironolactone in
CSC, including improved BCVA, reduced choroidal thickness, and re-
duced SRF (Bousquet et al., 2015; Chai et al., 2016; Chin et al., 2015;
Daruich et al., 2016; Falavarjani et al., 2017; Herold et al., 2014, 2017;
Kapoor and Wagner, 2016; Kim et al., 2018a; Pichi et al., 2017). In a
randomised controlled crossover study involving 15 patients with non-
resolving CSC, spironolactone treatment was associated with an
average reduction in choroidal thickness of 102 μm, compared to only
10 μm with placebo (Bousquet et al., 2015); the number of patients who
achieved complete resolution of the serous neuroretinal detachment
was not reported. In a prospective case series, 16 eyes with cCSC were
treated with 25mg spironolactone per day for at least 6 weeks, re-
sulting in complete resolution of SRF in 7 eyes (44%) and a significant
increase in BCVA compared to baseline (Falavarjani et al., 2017). In a
prospective clinical trial involving 21 eyes with cCSC treated with
25mg spironolactone twice daily, 15 eyes (71%) had decreased SRF on
OCT 12 months after the start of treatment (Herold et al., 2017). In
another prospective randomised controlled clinical trial involving 30
eyes with aCSC, a significantly higher percentage of eyes had complete
SRF resolution at two months in the spironolactone-treated group (10
out of 18 eyes, 56%) compared to the observed control group (1 out of
12 eyes, 8%) (Sun et al., 2018). Recently, Kim and colleagues retro-
spectively analysed the outcome after using spironolactone to treat 17
eyes with steroid-induced CSC; the authors found complete SRF re-
solution in 14 eyes (82%) of patients who remained on glucocorticoids
(Kim et al., 2018a). Despite these promising initial results, prospective
randomised controlled trials of sufficient power and duration are
needed in order to fully evaluate the clinical benefits of using spir-
onolactone for CSC.
2.3.6.2. Eplerenone. Similar to spironolactone, eplerenone is primarily
used to treat heart failure (Pitt et al., 2003). Eplerenone was originally
designed to avoid the hormone-associated side effects of
spironolactone, serving as a more selective MR antagonist due to the
addition of a 9,11-epoxide group (Cook et al., 2003; Delyani, 2000;
McMahon, 2001). Although eplerenone likely has more tolerable side
effects compared to spironolactone, eplerenone does not appear to be
clinically superior to ‒ and possibly not equivalent to ‒ spironolactone
in treating CSC (Chin et al., 2015; Pichi et al., 2017). However, after the
patent on eplerenone expired, the price difference between eplerenone
and spironolactone became negligible, and patients ‒ particularly male
patients ‒ should first try eplerenone, as it is far less likely to induce
gynaecomastia and mastalgia, aside from other possible side effects.
Before starting eplerenone treatment, the patient's serum potassium and
creatinine levels should be checked. Different approaches for the
monitoring of serum potassium exist, and the following protocol is an
example. Treatment with eplerenone should not be initiated if serum
potassium is > 5.5 mEq/L or if the creatinine clearance is≤ 30mL/
min. Patients usually commence with 1 dose of 25mg eplerenone a day.
Serum potassium should be reassessed after approximately 1 week. If
potassium is < 5.0 mEq/L, the eplerenone dose is increased (from
25mg daily to 50mg daily or from 25mg every other day to 25mg
daily). If serum potassium is between 5.0 and 5.4 mEq/L, eplerenone
treatment should remain at the current dose. If serum potassium is
between 5.5 and 5.9 mEq/L, eplerenone is reduced (from 25mg every
other day to withhold, from 25mg daily to 25mg every other day, or
from 50mg daily to 25mg daily). When serum potassium is≥ 6.0 mEq/
L, eplerenone treatment should be stopped, but can be restarted when
serum potassium levels fall below 5.5 mEq/L. Serum potassium levels
should be checked monthly, and the dosage should be adjusted
accordingly.
Patients taking eplerenone should be instructed to contact their
physician if they experience any side effects such as nausea, diarrhoea,
dizziness, or headache, which can occur in up to 10% of patients.
Similar to spironolactone, contraindications for eplerenone include the
use of potassium supplements, potassium-sparing diuretics, potent
CYP3A4 inhibitors, or combined treatment with an angiotensin-con-
verting enzyme inhibitor and angiotensin receptor blocker.
In a prospective pilot study, Bousquet and colleagues prescribed
eplerenone to 13 patients with cCSC and reported a reduction in SRF,
reduced central macular thickness, and improved BCVA (Bousquet
et al., 2013). Cakir and colleagues retrospectively reported that 29% of
patients with cCSC who failed to respond to oral acetazolamide, in-
travitreal bevacizumab, focal laser photocoagulation, or PDT achieved
complete resolution of SRF after a median of 106 days of daily epler-
enone (Cakir et al., 2016). Other studies have also shown that epler-
enone can have clinical value, as summarised in Table 4. Importantly,
an absence of CNV on OCT angiography and the presence of a focal
leakage point on ICGA may serve as predictive factors for complete
resolution of SRF following eplerenone treatment (Sacconi et al., 2018).
On the other hand, patients who present with widespread changes in
the RPE may benefit less from eplerenone treatment compared to pa-
tients who present without these abnormalities (Bousquet et al., 2019;
Cakir et al., 2016). The duration of eplerenone treatment in published
studies ranged from 1 month to 51 months (Table 4), and although the
effects of eplerenone in CSC should be evident within a few months,
information on when treatment effect may occur is scarce (Bousquet
et al., 2019; Rahimy et al., 2018; Schwartz et al., 2017). To date, no
large, prospective randomised controlled trials have been conducted in
order to measure the efficacy or long-term outcome of using eplerenone
or spironolactone to treat CSC. However, two prospective studies are
currently in progress; one study is designed to compare eplerenone with
sham treatment (VICI trial, ISRCTN registry: 92746680), and the other
is designed to compare eplerenone with half-dose PDT (SPECTRA trial,
ClinicalTrials.gov identifier: NCT03079141) (see sections 4.1 and 4.2).
2.3.6.3. Mifepristone. Mifepristone (also known as RU-486) is a
glucocorticoid antagonist that binds to the cytosolic glucocorticoid
receptor and prevents gene transcription by blocking recruitment of
coactivators, thus rendering the receptor complex inactive. In addition,
mifepristone competes with progesterone binding to the progesterone
receptor. Mifepristone is currently approved for pharmaceutically
induced abortion (Cadepond et al., 1997; Clark, 2008). Given that
steroids are the most important external risk factor for developing CSC,
stimulation of the glucocorticoid receptor may play a role in the
pathogenesis of CSC, thereby providing the rationale for using
mifepristone to treat CSC. In a prospective study of 16 patients with
cCSC who received 200mg/day mifepristone for up to 12 weeks, 5
patients (31%) had an improvement in BCVA of ≥5 ETDRS letters, with
no severe adverse events reported (Nielsen and Jampol, 2011).
Currently, a randomised placebo-controlled clinical trial designed to
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test the effects of mifepristone in 16 patients with CSC is underway
(STOMP-CSC, ClinicalTrials.gov identifier: NCT02354170), and the
results of this study are expected to be released in the near future.
2.3.7. Other systemic treatment strategies
A variety of other oral pharmaceutical-based treatments have been
reported, primarily from relatively small, retrospective studies (Salehi
et al., 2015). These studies should be interpreted with caution, as
spontaneous recovery is common in aCSC, and spontaneous improve-
ment and resolution can also occur in cCSC.
2.3.7.1. Antioxidants. Treatment with high-dose antioxidants was
studied in patients with aCSC in a randomised placebo-controlled
trial. In a group of 29 patients who received high-dose antioxidants,
22 (76%) achieved complete resolution of SRF, compared to 14 out of
29 patients (48%) who received placebo (Ratanasukon et al., 2012). It
is important to note that during this trial, patients were able to receive
additional treatments as needed, which complicates the analysis of the
putative effects of antioxidants. Oral administration of a curcumin-
phospholipid formulation, which purportedly has antioxidant and anti-
inflammatory properties, was found to reduce the height of the
neurosensory retinal detachment in 78% of 12 patients with CSC,
although no information was provided with respect to whether the
patients had aCSC or cCSC (Mazzolani, 2012; Mazzolani and Togni,
2013). According to the currently available evidence, there is no clear
indication for treating CSC using antioxidants.
2.3.7.2. Aspirin. Aspirin (acetylsalicylic acid) inhibits platelet
aggregation and may reduce serum levels of plasminogen activator
inhibitor 1, which can be increased in CSC (Iijima et al., 1999). A
prospective case series described a positive effect of aspirin in 109
patients with unspecified CSC patients; specifically, BCVA improved to
a larger extent in patients who were treated with aspirin compared to
historical control patients (Caccavale et al., 2010). However, because
the control group was based on retrospective data, the conclusions
should be interpreted with caution. Thus, there is currently extremely
limited evidence supporting the notion that aspirin is a viable treatment
for CSC with aspirin.
2.3.7.3. Beta-blockers. In a case report, Tatham and Macfarlane found
that treating two patients with recurrent CSC with the selective β1
receptor blocker metoprolol resulted in resolution of SRF in both
patients (Tatham and Macfarlane, 2006). In a small, randomised
controlled trial, the effect of the non-specific beta-blocker nadolol
was evaluated in 8 patients with unspecified CSC; the authors found
that the size of the subretinal detachment was reduced to a lesser extent
in patients who were treated with nadolol compared to patients who
received placebo (with an average decrease of 4.3mm2 and 16.0mm2,
respectively), although difference was not statistically significant
(Browning, 1993). This finding suggests that nadolol may actually
reduce the likelihood of achieving SRF resolution and is therefore
unlikely to be useful in treating CSC. Consistent with this notion, a
recent study found that a different non-specific beta-blocker ‒
metipranolol ‒ had no significant effect in patients with aCSC with
respect to resolving SRF compared to control-treated patients (Chrapek
et al., 2015). Taken together, the currently available evidence suggests
that beta-blockers are not likely to be a viable treatment for CSC.
2.3.7.4. Carbonic anhydrase inhibitors. Oral administration of the
carbonic anhydrase inhibitor dorzolamide was found to have clinical
benefits in treating cystoid macular oedema in patients with retinitis
pigmentosa (Grover et al., 1997). Subsequently, Wolfensberger and
colleagues hypothesised that acidification of the subretinal space
increases fluid resorption through the RPE, possibly due to a
perturbation in carbonic anhydrase type IV, leading to the proposal
that carbonic anhydrase inhibitors may be a viable option for treating
CSC (Wolfensberger et al., 1999). However, although a retrospective
study of 15 patients with unspecified CSC indicated that oral treatment
with the carbonic anhydrase inhibitor acetazolamide can reduce the
time until complete resolution of SRF compared to untreated control
group (3 weeks versus 8 weeks, respectively), BCVA and the rate of
recurrence did not differ between acetazolamide-treated and untreated
patients (Pikkel et al., 2002). Moreover, large, well-designed studies
designed to assess the clinical benefits of inhibiting carbonic anhydrases
in patient with CSC have not been performed. Thus, carbonic anhydrase
inhibitors are not likely to be a viable treatment for CSC.
2.3.7.5. Finasteride. Finasteride is an inhibitor of dihydrotestosterone
synthesis and is used to treat benign prostatic hyperplasia and hair loss.
Because androgens such as testosterone may play a role in CSC,
finasteride has been evaluated as a possible treatment for CSC
(Forooghian et al., 2011; Moisseiev et al., 2016). However, a pilot
study involving 5 patients with cCSC found that taking 5mg/day
finasteride for 3 months had no effect on BCVA measured at 6
months compared to baseline; the rate of SRF resolution was not
reported (Forooghian et al., 2011; Moisseiev et al., 2016). In contrast, a
retrospective review of 23 patients with cCSC found that 76% of
patients who were treated with finasteride had complete SRF
resolution after a mean follow-up duration of 15 months (Moisseiev
et al., 2016). With respect to side effects, two patients in the pilot study
by Forooghian and colleagues reported a loss of libido, whereas no side
effects were observed by Moisseiev and colleagues. These relatively
preliminary studies should be followed by larger studies in order to
evaluate whether finasteride treatment can benefit patients with CSC.
2.3.7.6. Helicobacter pylori eradication. Infection with the bacterium H.
pylori has been proposed as a risk factor for CSC, although this putative
association has not been demonstrated conclusively (Chatziralli et al.,
2017). H. pylori infection can be eradicated using metronidazole or
omeprazole together with amoxicillin and/or clarithromycin (Zavoloka
et al., 2016). Interestingly, successful eradication of H. pylori in patients
with unspecified CSC has been reported to lead to more rapid resolution
of SRF in a retrospective, comparative study of 25 patients compared to
25 untreated patients who did not have an H. pylori infection (Rahbani-
Nobar et al., 2011). With respect to aCSC, eradicating H. pylori was
found to improve retinal sensitivity but had no effect on BCVA or
complaints of metamorphopsia (Dang et al., 2013). Nonetheless, a
prospective, randomised, case-controlled, non-blinded study involving
33 patients with aCSC and H. pylori found that treating the H. pylori
infection improved BCVA and retinal sensitivity measured using
automated static perimetry (Zavoloka et al., 2016). As noted above,
there is currently no compelling evidence supporting the notion that H.
pylori infection is a major risk factor for CSC, and the evidence to date
to support the idea that eradicating H. pylori may serve as a possible
treatment for CSC is limited. Nevertheless, patients with CSC should be
tested for H. pylori if they present with symptoms associated with this
bacterial infection such as stomach ache or heartburn.
2.3.7.7. Ketoconazole. Ketoconazole is primarily used as an anti-fungal
agent, but it also has glucocorticoid receptor antagonising properties.
These glucocorticoid-related effects may be of clinical value in treating
CSC, as CSC may be associated with an upregulation of glucocorticoid
receptors. Two studies examined the effects of oral ketoconazole (200
or 600mg/day for 4 weeks) in 15 patients with aCSC and 5 patients
with cCSC (Golshahi et al., 2010; Meyerle et al., 2007). The authors
found that ketoconazole decreased endogenous urine cortisol levels, but
had no significant effect on visual acuity or serous neuroretinal
detachment; moreover, erectile dysfunction and nausea were reported
in one patient each. These results indicate that further study is
warranted before ketoconazole can be considered as a possible first-
line treatment for CSC.
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2.3.7.8. Melatonin. The effects of melatonin on the circadian rhythm
have been suggested to also have positive effects in CSC (Pandi-Perumal
et al., 2008). To test this hypothesis, Gramajo and colleagues performed
a prospective, comparative case study in which 13 cCSC patients were
treated with melatonin (Gramajo et al., 2015). The authors found that
the patients who received melatonin had a larger improvement in BCVA
compared to a control group. Moreover, 3 out of 13 treated patients
(38%) had complete resolution of SRF at the 1-month follow-up visit.
No side effects were reported. No additional evidence is available
regarding the use of melatonin in treating CSC; therefore, further study
is warranted.
2.3.7.9. Methotrexate. Methotrexate is an antimetabolic,
immunosuppressive drug used primarily in treating inflammatory
(caption on next page)
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disorders such as rheumatoid arthritis. Because of its non-
immunosuppressive properties ‒ for example, its interaction with
steroid receptors ‒ methotrexate may be beneficial for treating cCSC
(Kurup et al., 2012). Two studies tested this hypothesis, and both found
that treating patients with cCSC for 12 weeks with oral low-dose
methotrexate resulted in significant improvements in BCVA (Abrishami
et al., 2015; Kurup et al., 2012). Abrishami and colleagues
prospectively studied 23 patients and found that 13 patients (62%)
had complete resolution of SRF at their 6-month follow-up visit
(Abrishami et al., 2015). In a retrospective study by Kurup and
colleagues, 9 patients with cCSC were treated with low-dose
methotrexate for an average of 89 days, with 83% of patients
achieving complete resolution of SRF after an average treatment
duration of 12 weeks (Kurup et al., 2012). Although these results
suggest that additional well-designed randomised controlled trials are
warranted, methotrexate is a generally unattractive treatment option in
CSC, as it can have severe side effects, including bone marrow
suppression and pulmonary, hepatic, and renal toxicity.
2.3.7.10. Nonsteroidal anti-inflammatory drugs. Topical application of
the nonsteroidal anti-inflammatory drug (NSAID) nepafenac (0.1%) has
also been suggested for treating aCSC. Alkin and colleagues
retrospectively studied this hypothesis and found a significantly
larger improvement in BCVA after 6 months (from 0.19 to 0.09
LogMAR) in 31 eyes treated 3 times daily for 4 weeks or until
complete SRF resolution, compared to an untreated control group
(0.13–0.1 LogMAR); moreover, at the 6-month follow-up visit 14 out
of 17 eyes (82%) in the treatment group had complete resolution of
SRF, compared to 6 out of 14 eyes (43%) in the control group, and no
treatment-related or systemic side effects were reported (Alkin et al.,
2013). In a case report, Chong and colleagues reported that a patient
with aCSC who received topical ketorolac (another NSAID) had SRF
resolution after 18 weeks (Chong et al., 2012). These relatively small
studies should be supported by more robust evidence before NSAIDs
can be introduced into clinical practice for treating CSC.
2.3.7.11. Rifampicin. Rifampicin (or rifampin) is used primarily for its
antimicrobial properties, but it can also affect the metabolism of
endogenous steroids by upregulating cytochrome P450 3A4. The 5′-
untranslated region in the CYP3A4 gene includes glucocorticoid
regulatory elements that may be altered in CSC (Guengerich, 1999).
A prospective single-arm study of rifampicin (300mg twice daily for 3
months) showed that SRF resolved in 4 out of 14 eyes (29%) at 6
months; treatment was discontinued in two patients due to
cholelithiasis (in one patient) and increased blood pressure (in one
patient) (Shulman et al., 2016). Moreover, a single case report
described the resolution of SRF in a patient with cCSC 1 month after
the start of rifampicin treatment (300mg twice daily) (Steinle et al.,
2012). In addition, Venkatesh and colleagues performed a retrospective
analysis of patients with cCSC who were treated with rifampicin and
found that 4 eyes with focal leakage on FA (44%) had complete
resolution of SRF after an average follow-up of 10 months; in
contrast, the eyes with diffuse leakage on FA had persistent SRF
(Venkatesh et al., 2018). Finally, an observational clinical study of 38
eyes in 31 patients with idiopathic CSC revealed that rifampin (300mg
daily for 3 months) improved mean BCVA from 0.56 to 0.47 LogMAR
units measured 4 weeks after cessation of treatment (Khan et al., 2016).
Despite these promising results, further studies have low priority given
the side effects associated with rifampicin and the relatively slow
treatment response with CSC ‒ if at all ‒.
2.3.8. Other treatment modalities
Several small studies and case reports have described non-conven-
tional treatments for CSC, including wearing an eye patch (Earl et al.,
2014), intravitreal injections of dobesilate (Cuevas et al., 2012), and
acupuncture (Lu and Friberg, 1987). Interestingly, an ophthalmologist
with CSC reported that he was able to photocoagulate his own leak by
‘sungazing’ (Gartner, 1987).
3. Currently preferred treatments for CSC
Central serous chorioretinopathy is commonly divided into two
categories based on the duration of symptoms, the extent of leakage on
angiography, and the presence of RPE atrophy; these two categories are
aCSC and cCSC. Chronic CSC can be complicated by CNV and/or PCRD,
which may be viewed upon as specific complicated subcategories of
cCSC. According to the literature, most investigators support this in-
complete and relatively rudimentary classification of CSC. However,
there currently is no clear consensus regarding the criteria for classifi-
cation, and a better defined classification system is needed (Singh et al.,
2018). Our current lack of an established classification system com-
plicates the study of the natural disease progression of CSC, its ther-
apeutic management, and the design of interventional trials, which
must take into account the relatively early onset maculopathy, the
common spontaneous resolution of SRF, and the disease's relatively
benign course (Daruich et al., 2015; Mohabati et al., 2018c; Otsuka
et al., 2002). Narrowing the scope of clinical CSC subgroups may in-
fluence the treatment outcome and may help guiding the development
of treatments tailored to each clinical subtype of CSC (Daruich et al.,
2015). In this regard, safety is of the utmost importance when devel-
oping new treatment strategies for CSC, given that CSC usually presents
early in life and has a relatively benign disease course (Daruich et al.,
2015; Mohabati et al., 2018c; Otsuka et al., 2002).
3.1. Acute CSC
A summarising flowchart with a proposal for decision making in
treatment of aCSC is shown in Fig. 7. Because of the high rate of
spontaneous SRF resolution within three to four months in aCSC (Klein
et al., 1974; Yannuzzi, 2010), observation during the first four months
is the most widely used strategy, except in patients who require rapid
SRF resolution and visual rehabilitation, for example for professional
Fig. 7. Flowchart of the proposed treatment strategy for acute central serous chorioretinopathy. If there is current corticosteroid use, possible cessation should be discussed
with the patient.
1 Treat hyperfluorescent areas on indocyanine green angiography (ICGA) that correspond to the area of (focal) leakage on fluorescein angiography (FA) and
subretinal fluid on optical coherence tomography (OCT). In case of multiple areas with focal leakage, a large spot including all areas can be used, or multifocal
immediately sequential spots may be used, starting with the area including the fovea (if fovea is involved).
2 In case of only a small amount of residual subretinal fluid (SRF), a conservative approach may be followed, with a follow-up visit including OCT imaging after 1–3
months to see if SRF eventually resolves completely. In case of persistent/increased SRF at that stage, the downstream treatment path may be followed.
3 Half-dose or half-fluence photodynamic therapy (PDT) may be added in order to treat the choroidal dysfunction/pachychoroid factor of the disease, but limited data
is available to support this combined treatment. When a neovascular component of polypoidal choroidal vasculopathy (aneurysmal type 1 neovascularization) is
present, PDT (either full-dose, half-dose, or half-fluence) can also be added to anti-vascular endothelial growth factor treatment.
4 Another half-dose or half-fluence PDT can be performed, but full-dose with full-fluence PDT may also be considered.
Abbreviations in flow chart: CNV, choroidal neovascularisation; CSC, central serous chorioretinopathy; FA, fluorescein angiography; FAF, fundus autofluorescence;
ICGA, indocyanine green angiography; OCT, optical coherence tomography; OCTA, optical coherence tomography angiography; PDT, photodynamic therapy; RPE,
retinal pigment epithelium; SRF, subretinal fluid; VEGF, vascular endothelial growth factor.
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reasons, or in cases with outer segment atrophy and/or granular debris
in the subretinal space. Although aCSC often resolves spontaneously,
retinal damage can still occur in the early phases and may progress as
long as the serous neuroretinal detachment persists due to SRF accu-
mulation (Hata et al., 2013). An essential insight gained with OCT is
that the SRF may not be resolved, yet the residual subfoveal fluid can be
so shallow that it evades detection by slit-lamp biomicroscopy (Wang
et al., 1999). This residual detachment can still lead to atrophy of
photoreceptor outer segments and vision loss over a period of years
(Wang et al., 2002). Thus, the prevailing clinical recommendation of
Fig. 8. Flowchart of the proposed treatment strategy for chronic central serous chorioretinopathy. If there is current corticosteroid use, possible cessation should be
discussed with the patient.
1 Treat hyperfluorescent areas on indocyanine green angiography (ICGA) that correspond to the area of (focal) leakage on fluorescein angiography (FA) and
subretinal fluid on optical coherence tomography (OCT). In case of multiple areas with focal leakage, a large spot including all areas can be used, or multifocal
immediate sequential spots may be used, starting with the area including the fovea (if fovea is involved).
2 In case of only a small amount of residual subretinal fluid (SRF), a conservative approach may be followed, with a follow-up visit including OCT imaging after 1–3
months to see if SRF eventually resolves completely. In case of persistent/increased SRF at that stage, the downstream treatment path may be followed.
3 Half-dose or half-fluence photodynamic therapy (PDT) may be added in order to treat the choroidal dysfunction/pachychoroid factor of the disease, but limited data
is available to support this combined treatment. When a neovascular component of polypoidal choroidal vasculopathy (aneurysmal type 1 neovascularization) is
present, PDT (either full-dose, half-dose, or half-fluence) can also be added to anti-vascular endothelial growth factor treatment.
4 Another half-dose or half-fluence PDT can be performed, but full-dose with full-fluence PDT may also be considered.
Abbreviations in flow chart: CNV, choroidal neovascularisation; CSC, central serous chorioretinopathy; FA, fluorescein angiography; FAF, fundus autofluorescence;
ICGA, indocyanine green angiography; OCT, optical coherence tomography; OCTA, optical coherence tomography angiography; PDT, photodynamic therapy; RPE,
retinal pigment epithelium; SRF, subretinal fluid; VEGF, vascular endothelial growth factor.
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waiting four months after presentation before considering intervention
is not strongly supported by objective evidence. This recommendation
also fails to take into consideration the fact that OCT can be used to
diagnose atrophic photoreceptor outer segments due to months or years
of chronic foveal SRF, even in the absence of RPE abnormalities (Wang
et al., 2005).
The goals of an intervention in aCSC should be to reduce the time
needed to restore vision and to stabilise the visual prognosis. In prac-
tice, this means that SRF should be resolved and recurrent serous
neuroretinal detachment should be prevented. Although some treat-
ments such as PDT, HSML, and eplerenone can decrease the time
needed to achieve complete resolution of SRF (Arora et al., 2018; Chan
et al., 2008a; Sun et al., 2018; Zucchiatti et al., 2018), solid data from
large prospective trials are currently lacking, particularly with respect
to HSML and eplerenone.
Photocoagulation of a focal leak on angiography can sometimes lead
to the rapid and complete resolution of SRF; however, these ‘ideal’ cases
‒ which have a solitary source of leakage at a relatively safe distance
from the fovea ‒ are uncommon, and limited evidence is available with
respect to long-term efficacy and safety (Leaver and Williams, 1979).
Photocoagulation does not clearly address the underlying choroidal
leakage, and it carries the risk of inducing CNV, symptomatic para-
central scotoma, and/or a chorioretinal adhesion with secondary in-
traretinal cystoid oedema (Cardillo Piccolino et al., 2008a; Wang et al.,
2008).
Half-dose PDT was shown to increase the likelihood of SRF resolu-
tion and improved visual outcome in the sole reasonably-sized pro-
spective, double-masked, placebo-controlled, randomised clinical trial
in aCSC conducted to date (Chan et al., 2008a). In addition, retro-
spective evidence suggests that the risk of recurrence of SRF leakage in
aCSC is reduced following PDT (Lu et al., 2016; Nicholson et al., 2013;
Ober et al., 2005). Based on current evidence, relatively early treatment
(within 4 months of presentation) with half-dose PDT may be con-
sidered the treatment of choice in patients with active aCSC who had
previous episodes of SRF, patients with bilateral disease activity, and/
or patients who rely on their vision for professional reasons. In the
event of persistent SRF following half-dose PDT (and upon re-
consideration of the initial diagnosis), the clinician may consider re-
treatment or another treatment strategy such as an MR antagonist or
HSML. ICGA-guided PDT may be the treatment of choice for aCSC, as it
may also target the primary choroidal abnormalities; however, large,
prospective randomised studies are needed in order to establish a clear
basis for an evidence-based approach to treating aCSC.
3.2. Chronic CSC
A summarising flowchart with a proposal for decision making in
treatment of cCSC is shown in Fig. 8. The persistence of SRF in cCSC is
associated with partly irreversible, progressive photoreceptor damage,
leading to loss of visual acuity and an accompanying loss of vision-
related quality of life (Breukink et al., 2017; Mrejen et al., 2019;
Nicholson et al., 2013). Therefore, the aim of treatment should be to
stop this progression and to improve vision. The most commonly used
treatments for cCSC are PDT, eplerenone, HSML, and argon laser pho-
tocoagulation.
HSML can induce complete resolution of SRF in 14–71% of CSC
patients (Lanzetta et al., 2008; Ricci et al., 2009; van Dijk et al., 2018b),
with a more favourable outcome in patients with a focal leakage spot on
FA compared to patients with diffuse leakage (Chen et al., 2008). The
PLACE trial, an investigator-initiated study, is the only large, pro-
spective multicentre randomised controlled trial comparing ICGA-
guided 810 nm HSML with ICGA-guided half-dose PDT in patients with
cCSC (van Dijk et al., 2018b). In this trial, half-dose PDT was superior to
HSML in terms of both short-term (6–8 weeks post-treatment) complete
resolution of SRF (51% versus 14% of patients, respectively) and long-
term (7–8 months post-treatment) complete resolution of SRF (67%
versus 29% of patients, respectively). Moreover, at 6–8 weeks, both the
increase in BCVA and retinal sensitivity on microperimetry were sig-
nificantly higher in the half-dose PDT group compared to the HSML
group (van Dijk et al., 2018b). No comparable data are available for
HSML using a 577 nm laser. In addition to significant differences in
treatment efficacy measured the PLACE trial, the value of using HSML
to treat cCSC is further complicated by the wide range of treatment
regimens, laser settings, and wavelengths that have been reported thus
far (Wood et al., 2017).
Treatment with MR antagonists has been associated with complete
resolution of the neuroretinal detachment in 20–66% of patients
(Bousquet et al., 2013; Cakir et al., 2016; Daruich et al., 2016; Rahimy
et al., 2018; Rajesh et al., 2018; Sampo et al., 2016; Singh et al., 2015).
Although spironolactone and eplerenone appear to be similarly effec-
tive at their respective preferred doses (Pichi et al., 2017), eplerenone is
preferred due to its favourable safety profile. Recurrences of SRF are
more likely to occur after spironolactone than after half-dose PDT (Kim
et al., 2019). The current evidence available from clinical studies is
considerably less convincing for MR antagonists compared to PDT and
HSML, which stems primarily from retrospective studies that reported
lower rates of SRF resolution compared to PDT.
The results of the PLACE trial are supported by a large body of
retrospective evidence indicating that 62–100% of patients with cCSC
can achieve complete SRF resolution following PDT (Lai et al., 2016;
Nicolo et al., 2012; Stewart, 2006; Tseng and Chen, 2015), with re-
ported patients numbers that are vastly higher than those studied in
both HSML and eplerenone treatment. Although no large study has
compared MR antagonists with PDT, such a study is currently underway
(see section 4.2, SPECTRA trial). Importantly, the risk of treatment-
related side effects is relatively low, and neither eplerenone nor PDT
treatment appears to induce permanent damage to the choriocapillaris
(Rabiolo et al., 2018).
Laser photocoagulation may be considered for patients with cCSC
with focal leakage located outside of the macular area, for example
when PDT is either unavailable at the treatment centre or cost-prohi-
bitive. However, long-term outcome following photocoagulation does
not appear to be superior to no treatment (i.e. observation), although
the evidence to date is relatively scarce (Gilbert et al., 1984). On the
other hand, other treatments such as half-dose PDT do not have these
limitations and have good long-term safety profiles, with few reported
side effects (Tseng and Chen, 2015).
Based on currently available data, half-dose or half-fluence PDT
appears to be the most effective and safest treatment for cCSC without
additional complications. However, it should be noted that half-dose
PDT treatment with verteporfin is considerably more expensive com-
pared to some other treatments, and requires the use of a specific laser
machine. When half-dose PDT is unavailable and/or cost-prohibitive,
other treatments can be considered, including focal argon laser at ec-
centric focal leakage points on FA, MR antagonists, and HSML
(Chhablani et al., 2014; Nicholson et al., 2013); the choice of treatment
should be based on a case-by-case discussion, as robust evidence with
respect to these non-PDT treatment modalities is currently lacking.
Half-dose or half-fluence PDT may also be considered in symptomatic
cCSC patients with SRF outside the fovea (van Dijk et al., 2017a). In the
case of persistent SRF following half-dose PDT, re-treatment with PDT
or another treatment such as MR antagonists or HSML may be con-
sidered (Scholz et al., 2015). Moreover, further research ‒ preferably
prospective studies ‒ is needed in order to determine whether the re-
latively small subgroup of patients who have extensive atrophic RPE
changes that include the fovea should be excluded from PDT due to the
risk of irreversible mild to moderate vision loss, which was reported to
occur in up to 2% of patients in this highly specific subtype of severe
cCSC (Mohabati et al., 2018b). Alternative treatments such as MR an-
tagonists and HSML may be considered in this subgroup of patients with
severe cCSC that includes atrophic RPE changes affecting the fovea,
even though these treatments appear to be less effective than PDT in
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accomplishing resolution of SRF accumulation in these cases (Ramos-
Yau et al., 2018; Zola et al., 2018).
3.2.1. Chronic CSC complicated by subretinal neovascularisation
Macular subretinal neovascularisation can occur in patients with
CSC, and presents most often in patients with severe cCSC (Peiretti
et al., 2015) (Fig. 3). Moreover, CNV was reported to occur in 2–18% of
cCSC patients (Fung et al., 2012; Loo et al., 2002; Nicholson et al.,
2018; Shiragami, 2018; Spaide et al., 1996a). Although CNV can be
present at the start of a CSC episode, it can also develop gradually,
particularly in patients over the age of 50 and/or patients with pro-
longed disease. Subretinal leakage from type 1 (sub-RPE) neovascu-
larisation due to pachychoroid neovasculopathy can mimic un-
complicated cCSC (Fung et al., 2012; Pang and Freund, 2015). CNV can
be identified using multimodal imaging techniques such as OCT, FA,
ICGA, and ‒ in particular ‒ OCT angiography (Fig. 3), although this
detection can be challenging in small, early-stage CNV and severe cCSC
with extensive chorioretinal abnormalities. Therefore, it may not be
uncommon for a patient to be initially diagnosed with having CSC
without CNV, even though a small CNV may have actually been present
at the time of diagnosis. The clinician should suspect CNV particularly
in patients who were relatively old at onset, have a mid/hyperreflective
signal below a flat irregular RPE detachment (Fig. 3A), a putative CNV
structure on OCT angiography (Fig. 3F and G), and/or a well-demar-
cated CNV ‘plaque’ (with or without a polypoidal component) on ICGA
(Fig. 3E). Because up to two-thirds of patients with CSC with CNV can
have a polypoidal component, ICGA is an important imaging tool for
identifying and localising these polypoidal structures.
The standard treatment for CSC complicated by active subretinal
CNV is intravitreal anti-VEGF treatment possibly supplemented by half-
dose or half-fluence PDT, as several studies have demonstrated good
efficacy in these cases (Chhablani et al., 2015, 2016; Lai et al., 2018;
Peiretti et al., 2018). For example, the MINERVA study found that in-
travitreal ranibizumab is effective in CNV with an unusual origin, in-
cluding CNV due to CSC (Lai et al., 2018). At the primary endpoint (2
months), the authors found that eyes with CNV due to CSC treated with
ranibizumab had an improvement in BCVA of 6.6 ETDRS letters,
compared with only 1.6 letters in the sham group (Lai et al., 2018).
With respect to polypoidal choroidal vasculopathy, large randomised
controlled trials based on the EVEREST II and PLANET studies found
that a combination of full-dose PDT and intravitreal ranibizumab or
aflibercept were beneficial (Koh et al., 2017; Lee et al., 2018). In ad-
dition, Peiretti and colleagues recently reported that 50% of polypoidal
lesions were closed after full-fluence PDT monotherapy, compared to
25% of lesions in patients who received anti-VEGF monotherapy
(Peiretti et al., 2018). An interesting group of patients with vascularised
CSC is characterised by flat irregular PEDs in which a thin neovascular
network can be detected on OCT angiography but not with other ima-
ging techniques (Quaranta-El Maftouhi et al., 2015). This so-called
‘silent type 1 CNV’ may actually be quite common in cCSC (Quaranta-El
Maftouhi et al., 2015). However, given that the contribution of this type
of CNV to subretinal leakage, as well as its role in the progression of
vision loss, has not been investigated, the use of anti-VEGF therapy in
these cases should be weighed carefully and may be deferred until ac-
tive leakage becomes evident.
3.2.2. Severe chronic CSC
Because of the likelihood of progressing to severe vision loss,
treatment should be advocated for patients with cCSC complicated by
PCRD. However, the efficacy of standard PDT and half-dose PDT is
relatively poor in this patient group (Cardillo Piccolino et al., 2003;
Nicolo et al., 2012). Using various reduced-setting PDT protocols in 25
eyes with severe cCSC with PCRD, Mohabati and colleagues achieved
complete resolution of intraretinal fluid in 11 eyes (44%), reduced
PCRD in 12 eyes (48%), and observed no changes in 2 eyes (8%) at first
visit after treatment (Mohabati et al., 2018b). In contrast, Silva and
colleagues reported complete resolution of intraretinal fluid in 10 out of
10 patients with cCSC and PCRD after treatment with full-setting PDT
(Silva et al., 2013). The relatively poor responses to PDT could be due
to the degenerative pathophysiological nature of PCRD in cCSC, in
which factors other than persistent SRF and choroidal-RPE dysfunction
become relevant once PCRD becomes chronic. Inconsistent results ob-
tained after using PDT for cCSC with PCRD ‒ regardless of the PDT
setting used ‒ may also be due to relatively common presence of diffuse
atrophic RPE changes, which can make it difficult to select the area for
laser treatment. In evaluating these results, it should be also noted that
intraretinal fluid may be reabsorbed at a slower rate than SRF (Cardillo
Piccolino, 2010; Mohabati et al., 2018b). Moreover, a strong topo-
graphic correlation has been found between the cystoid intraretinal
spaces and points of chorioretinal adherence at the site of subretinal
atrophy and fibrosis (Cardillo Piccolino et al., 2008a, 2008b). Sub-
retinal fibrotic scars have also been reported to develop from subretinal
fibrin in eyes with severe CSC (Schatz et al., 1995). These scars may
represent focal areas of chorioretinal adherence and breakdown of the
RPE barrier, providing a direct passage for fluid to diffuse from the
choroid into the retina in the case of choroidal hyperperfusion (Cardillo
Piccolino et al., 2008a, 2008b). OCT angiography, FA, and/or ICGA
should be performed to rule out the possibility of CNV in patients with
cCSC patients with intraretinal fluid, as up to 45% of these cases may
indeed have CNV and should be treated accordingly (see section 3.2.1)
(Sahoo et al., 2019).
3.3. Unclear cases
Some patients do not fit into the classification systems discussed
above. For example, in some cases the presence of CNV can be am-
biguous. In cases in which the diagnosis is not clear, determining the
optimal treatment can be challenging. In such cases, the treatment
strategy may depend on a variety of factors, including the patient's
wishes, the BCVA and age, the prognosis with respect to disease pro-
gression, the treating physician's personal preferences, and a range of
other clinical and non-clinical parameters.
4. Future perspectives
The results of several ongoing prospective randomised controlled
clinical trials will be available in the next few years. These studies in-
clude the investigator-initiated multicentre VICI and SPECTRA trials,
both of which are expected to report their results within the coming two
years.
4.1. VICI trial
The VICI trial (‘Clinical efficacy and mechanistic evaluation of
eplerenone for central serous chorio-retinopathy – the VICI randomised
trial’; ISRCTN registry: 92746680) is the first large, prospective multi-
centre randomised placebo-controlled trial designed to investigate the
use of eplerenone in treating cCSC (Willcox et al., 2019). In this trial,
104 patients with cCSC are randomly allocated to receive either
eplerenone or sham treatment. The primary outcome of the VICI trial is
BCVA measured at the 12-month follow-up visit. Secondary outcomes
include low luminance visual acuity, central macular thickness, height
of the SRF, choroidal thickness, and adverse events. The placebo-con-
trolled aspect of this trial will provide valuable information regarding
the natural course of cCSC, as both aCSC and cCSC can resolve spon-
taneously without treatment.
4.2. SPECTRA trial
The Study on half-dose Photodynamic therapy versus Eplerenone in
chronic CenTRAl serous chorioretinopathy (SPECTRA trial,
ClinicalTrials.gov identifier: NCT03079141) is the first prospective
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multicentre randomised controlled trial designed to compare half-dose
PDT with eplerenone treatment with respect to achieving complete
resolution of SRF and improving the quality of vision. This study fol-
lows the PLACE trial, in which PDT was found to be superior to treat-
ment with HSML in cCSC (van Dijk et al., 2018b). The target number of
patients to be included in the SPECTRA trial is 107. The primary end-
point of the SPECTRA trial is a measure of the difference between half-
dose PDT and eplerenone treatment in patients with cCSC in terms of
both complete resolution of SRF on OCT and safety. The secondary
functional endpoints include BCVA (in ETDRS letters), retinal sensi-
tivity on macular microperimetry, and vision-related quality of life
measured using a validated questionnaire (NEI-VFQ-25). Additional
secondary endpoints include the number of patients who receive
crossover treatment in each treatment arm, the mean change in ETDRS
BCVA over time among those patients with subsequent treatment (i.e.
crossover) and patients without subsequent treatment, and the mean
changes in ETDRS BCVA, retinal sensitivity, and NEI-VFQ-25 over time.
These parameters are obtained up to two years after enrolment.
4.3. Towards an evidence-based treatment guideline
The results of these trials and other large studies will likely lead to
an evidence-based treatment guideline for CSC. At the same time, it is
just as important to more accurately define the subtypes of CSC by
performing detailed multimodal imaging studies. These studies will
facilitate reaching a consensus regarding the classification of CSC,
which is urgently needed given that the optimal treatment strategy
likely differs among CSC subtypes. It is also essential that intervention
studies use comparable clinical endpoints and aim to achieve complete
resolution of the serous neuroretinal detachment (van Rijssen et al.,
2018a). In this respect, artificial intelligence and ‘deep learning’ are
likely to become important in the diagnosis and follow-up care of ret-
inal diseases, including CSC (De Fauw et al., 2018). For example, arti-
ficial intelligence can be used to discover new characteristics and
prognostic markers in CSC by analysing large amounts of annotated
multimodal imaging data. Deep learning protocols and artificial in-
telligence may also reveal CSC-specific patterns on multimodal ima-
ging. With the addition of clinical parameters, it may one day be pos-
sible to develop an algorithm to support treatment decisions. Moreover,
large studies regarding genetic and other risk factors may shed new
light on the pathophysiology of CSC. For example, recent studies re-
vealed similar genetic risk loci with partly opposite effects between CSC
and AMD (Miki et al., 2018; Mohabati et al., 2018; Schellevis et al.,
2018). These findings may also have future implications for treating
CSC. With the ability to culture choroidal endothelial cells (Brinks
et al., 2018), it may now be possible to study the effects of various
substances such as corticosteroids using an in vitro approach. Studies
involving these in vitro choroidal cell models may eventually lead to the
identification of pathophysiological pathways in CSC and help develop
new treatment strategies for CSC. Another emerging topic of interest
that warrants further study with respect to preventing and treating CSC
is based on the haemodynamic condition of patients with CSC. A
growing body of evidence suggests that patients with CSC may have a
functional change in the physiological mechanisms that regulate chor-
oidal blood flow, and this change may even be induced by emotional
and/or physical stress (Cardillo Piccolino et al., 2018; Roybal et al.,
2018; Tittl et al., 2005).
5. Conclusions
The classification and treatment of CSC has long been ‒ and remains
today ‒ subject to controversy. In recent years, several relatively large
studies regarding the treatment of CSC have been published, some of
which were conducted in a multicentre prospective randomised con-
trolled setting. Based on the subtypes of CSC that were roughly defined
in these studies, the treatment outcomes and treatment strategies of
choice are slowly evolving. With respect to aCSC, treatment can often
be deferred, unless specific circumstances such as professional reliance
on optimal vision indicate intervention. When treatment is indicated in
aCSC, the current evidence suggests that half-dose or half-fluence PDT
guided by either ICGA or FA may be the treatment of choice for ac-
celerating SRF resolution, improving vision, and decreasing the risk of
recurrence.
Based on efficacy and safety data from retrospective and prospective
studies such as the prospective multicentre randomised controlled
PLACE trial, half-dose (or half-fluence) PDT should be considered the
treatment of choice for cCSC. Thus, the available evidence to support
the use of PDT in cCSC may also alleviate current restrictions in re-
imbursement for this off-label treatment indication. In elderly patients
who present with a clinical picture of CSC, the presence of a shallow
RPE detachment with mid- or mixed reflectivity below the RPE de-
tachment is highly suggestive of a neovascular membrane, which can be
confirmed using OCT angiography and ICGA. ICGA can also be used to
visually determine whether such a sub-RPE neovascular membrane has
a polypoidal component. Evidence suggests that these CSC cases with
subretinal CNV should be treated using intravitreal injections of anti-
VEGF compounds and/or half-dose or half-fluence PDT. In the case of
polypoidal choroidal vasculopathy, intravitreal anti-VEGF either as a
monotherapy or combined with PDT should be considered for targeting
the choroidal abnormalities such as pachychoroid and hyperperme-
ability, as well as the neovascular and/or polypoidal component. Large
multicentre randomised controlled trials are currently underway and
will likely shed more light on the efficacy of various treatments such as
eplerenone, providing a better comparative overview of the principal
treatment options that are currently available. The controversy re-
garding the classification of CSC and the desired clinical endpoints of
treatment remain important topics that will need to be addressed in
order to optimise the design of future randomised controlled trials. The
outcome of these studies will certainly facilitate the establishment of an
evidence-based treatment guideline for CSC.
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